

1 Quantification of Fundus
2 Autofluorescence Features in a
3 Molecularly Characterized Cohort of
4 More Than 3000 Inherited Retinal
5 Disease Patients from the United
6 Kingdom

7 William Woof^{1,2*}, Thales A. C. de Guimarões^{1,2*}, Saoud Al-Khuzaei^{3*}, Malena Daich Varela^{1,2*},
8 Sagnik Sen^{2,1*}, Pallavi Bagga^{1,2}, Bernardo Mendes^{1,2}, Mital Shah^{1,2}, Paula Burke⁴, David
9 Parry⁴, Siying Lin^{1,2}, Gunjan Naik^{1,2}, Biraja Ghoshal^{1,2}, Bart Liefers^{1,8}, Dun Jack Fu^{1,2},
10 Michalis Georgiou^{1,2}, Quang Nguyen^{1,2}, Alan Sousa da Silva², Yichen Liu¹, Yu Fujinami-
11 Yokokawa⁶, Nathaniel Kabiri², Dayyanah Sumodhee^{1,2}, Praveen Patel^{1,2}, Jennifer Furman¹,
12 Ismail Moghul^{1,2}, Juliana Sallum⁷, Samantha R. De Silva³, Birgit Lorenz⁵, Frank Holz⁵, Kaoru
13 Fujinami⁶, Andrew R Webster^{1,2}, Omar Mahroo^{1,2}, Susan M. Downes³, Savita Madhusuhan⁴,
14 Konstantinos Balaskas^{1,2*}, Michel Michaelides^{1,2*}, Nikolas Pontikos^{1,2*}

15

16 ¹ University College London Institute of Ophthalmology, 11-43 Bath Street, London , UK

17 ² Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK

18 ³ Oxford Eye Hospital, John Radcliffe Hospital, Oxford OX3 9DU, UK

19 ⁴ St Paul's Eye Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool , UK

20 ⁵ Transmit Centre of Translational Ophthalmology % Justus-Liebig-Universität Giessen, Germany

21 ⁶ Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs,

22 National Hospital Organization Tokyo Medical Center

23 ⁷ Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Federal University
24 of Sao Paulo

25 ⁸ Department of Ophthalmology and Epidemiology, Erasmus MC, Rotterdam, The Netherlands

26

27 * Authors contributing equally

28

29 Corresponding author: n.pontikos@ucl.ac.uk

30

31 Abstract

32 **Purpose:** To quantify relevant fundus autofluorescence (FAF) image features cross-
33 sectionally and longitudinally in a large cohort of inherited retinal diseases (IRDs) patients.

34 **Design:** Retrospective study of imaging data (55-degree blue-FAF on Heidelberg Spectralis)
35 from patients.

36 **Participants:** Patients with a clinical and molecularly confirmed diagnosis of IRD who have
37 undergone FAF 55-degree imaging at Moorfields Eye Hospital (MEH) and the Royal
38 Liverpool Hospital (RLH) between 2004 and 2019.

39 **Methods:** Five FAF features of interest were defined: vessels, optic disc, perimacular ring of
40 increased signal (ring), relative hypo-autofluorescence (hypo-AF) and hyper-
41 autofluorescence (hyper-AF). Features were manually annotated by six graders in a subset
42 of patients based on a defined grading protocol to produce segmentation masks to train an
43 AI model, AIRDetect, which was then applied to the entire imaging dataset.

44 **Main Outcome Measures:** Quantitative FAF imaging features including area in mm² and
45 vessel metrics, were analysed cross-sectionally by gene and age, and longitudinally to
46 determine rate of progression. AIRDetect feature segmentation and detection were validated
47 with Dice score and precision/recall, respectively.

48 **Results:** A total of 45,749 FAF images from 3,606 IRD patients from MEH covering 170
49 genes were automatically segmented using AIRDetect. Model-grader Dice scores for disc,
50 hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68 and 0.65. The
51 five genes with the largest hypo-AF areas were *CHM*, *ABCC6*, *ABCA4*, *RDH12*, and *RPE65*,
52 with mean per-patient areas of 41.5, 30.0, 21.9, 21.4, and 15.1 mm². The five genes with the
53 largest hyper-AF areas were *BEST1*, *CDH23*, *RDH12*, *MYO7A*, and *NR2E3*, with mean
54 areas of 0.49, 0.45, 0.44, 0.39, and 0.34 mm² respectively. The five genes with largest ring
55 areas were *CDH23*, *NR2E3*, *CRX*, *EYS* and *MYO7A*, with mean areas of 3.63, 3.32, 2.84,
56 2.39, and 2.16 mm². Vessel density was found to be highest in *EFEMP1*, *BEST1*, *TIMP3*,
57 *RS1*, and *PRPH2* (10.6%, 10.3%, 9.8%, 9.7%, 8.9%) and was lower in Retinitis Pigmentosa
58 (RP) and Leber Congenital Amaurosis genes. Longitudinal analysis of decreasing ring area
59 in four RP genes (*RPGR*, *USH2A*, *RHO*, *EYS*) found *EYS* to be the fastest progressor at
60 -0.18 mm²/year.

61 **Conclusions:** We have conducted the first large-scale cross-sectional and longitudinal
62 quantitative analysis of FAF features across a diverse range of IRDs using a novel AI
63 approach.

64
65
66

67 Introduction

68 Inherited retinal diseases (IRDs) are clinically and genetically heterogeneous disorders that
69 affect the retina, and represent the leading cause of certifiable blindness among working-age
70 adults in England and Wales and the second commonest cause in childhood ¹. This group of
71 disorders can be caused by genetic mutations in any one of over 270 genes ²⁻⁴.

72

73 Many IRDs are associated with structural changes within the retina, which can be detected
74 with retinal imaging using different imaging modalities such as colour fundus, infrared-
75 reflectance (IR), spectral-domain optical coherence tomography (SD-OCT), or fundus
76 autofluorescence (FAF). FAF is of particular importance in the context of IRDs, as it allows
77 the detection of patterns of fluorophores, often at the level of the photoreceptors and retinal
78 pigment epithelium (RPE), which can be indicative of pathological changes such as loss of
79 overlying photoreceptors ^{5,6}. Some of these FAF signal changes are highly characteristic of
80 specific IRDs and can indicate features such as areas of RPE atrophy or lipofuscin deposits.
81 FAF is listed as a primary or secondary outcome in multiple clinical trials, and it has become
82 a useful retinal biomarker for diagnostic and prognostication purposes in a wide variety of
83 IRDs ^{3,7,8}.

84

85 The identification and quantification of features of degeneration within retinal imaging is
86 critical for diagnosis, monitoring disease progression, providing prognostic information and
87 assessing treatments in IRDs. The first steps in quantifying retinal imaging-based
88 biomarkers of disease involves identification and segmentation of these features. Manual
89 segmentation performed by human annotators is time consuming and requires expert
90 annotators, which makes this process subjective and not feasible on a large scale.
91 Automated identification and segmentation of IRD features in a reliable way is important for
92 enabling the routine use of these data quantitatively in clinical practice and to help further
93 our understanding of these diseases.

94

95 Existing studies that have used deep learning to segment IRD features from retinal images
96 have so far focused on specific IRD phenotypes such as retinitis pigmentosa (RP), Stargardt
97 (STGD1), and choroideremia (CHM) ^{9,10}.

98

99 To support our analysis on a broad range of different IRD phenotypes, we develop
100 AIRDetect, a deep learning model that can automatically identify and segment relevant
101 features from FAF images. We apply AIRDetect to the entire cohort of IRD patients with
102 molecularly confirmed diagnoses at Moorfields Eye Hospital, to identify gene-phenotype
103 associations, as well as quantify disease progression.

104

105 **Methods**

106 **Dataset Curation**

107 Patients' genotypes were extracted from the Genetics database of Moorfields Eye Hospital
108 (MEH, London, UK)^{2,11}. Patients' images were exported from the Heidelberg Imaging
109 (Heyex) database (Heidelberg Engineering, Heidelberg, Germany) based on their hospital
110 number, for records between 2004-06-17 and 2019-10-22. All 55-degree FAF images were
111 488nm blue-FAF images captured by the Heidelberg Spectralis imaging platform.

112

113 A dataset of 736 blue-FAF images (55-degree) from 573 patients from MEH were annotated
114 with four different image features, optic disc, regions of hyper- and hypo-autofluorescence
115 (AF), and perimacular ring of increased signal, and a further set of 206 blue-FAF images
116 (55-degree) from 127 patients from the Royal Liverpool Hospital (RLH) were annotated with
117 the retina vessel tree. A grading protocol was defined for IRD retinal feature annotations
118 (**Table 1**)¹². The Dice similarity coefficient score was used to assess inter-grader agreement
119 ¹³. Manual grading was completed over an 18-month period from June 2022 to December
120 2023 by four graders, with two additional graders carrying out the vessel segmentation at
121 RLH. Manual grading was performed using the Moorfields Grading Portal online platform
122 (grading.readingcentre.org). A full breakdown of the manually annotated dataset is given in

123 **Supplementary Table 1.**

124

125

| Name | Shorthand | Includes | Excludes |
|--------------------------------------|-----------|---|--|
| Optic Disc | disc | The optic nerve head. Includes both the optic cup and rim. | Peripapillary atrophy not included in annotation. |
| Hypo-autofluorescence | hypo-AF | Areas distinctly darker than physiological normal area with 50% grader confidence. The level of hypo-AF should be at least 90-100% as dark as the optic disc. Note this is relative AF rather than absolute AF. | Excludes peripapillary atrophy. Areas of ambiguous (not definitely decreased) regions in the periphery are not annotated as hypo-AF. |
| Hyper-autofluorescence | hyper-AF | Regions brighter than physiological normal area with 50% grader confidence. Note this is relative AF rather than absolute AF. | Excludes macular ring. Excludes flecks. |
| Perimacular ring of increased signal | ring | Ring shaped area of hyper-AF within the vascular arcades at the macula. | Must be >50% complete circle. |
| Veins and Arteries | vessels | All visible retinal vessels stemming from the optic disc. | Only annotated over atrophy if the grader is more than 50% certain of the location of the vessel. |

126 **Table 1:** Features and definitions used during the annotation process of five features by the graders.

127

128

129 Training and Test Datasets

130 The annotated dataset was compiled, and any images without confirmation for all features
 131 from at least one grader at the time of model development were discarded, and, to avoid
 132 bias, the annotation from a single grader was randomly selected where grader annotations
 133 were available for a single image. After this process there were 554 images from 464
 134 patients from MEH. The MEH training set consisted of 506 images from 424 patients from.
 135 The MEH hold-out test set consisted of 48 images from 40 patients. The RLH training set
 136 consisted of 72 images from 52 patients from RLH. The RLH hold-out test set consisted of
 137 23 images from 22 patients. Training sets were split into five separate sets for use with 5-fold
 138 cross validation, ensuring a balanced representation of each class across folds. Assignment
 139 to the training and test sets was done at patient-level to avoid any potential data leakage.
 140 The data flowchart is fully described in **Supplementary Figure 1**.

141

142 Development of AIRDetect Segmentation Model

143 For training the AIRDetect segmentation model, we selected the nnU-Net (no-new-UNet)
 144 framework for its adaptability and performance in automatic medical image segmentation
 145 tasks¹⁴. At its core, nnU-Net leverages a fully convolutional network design inspired by the
 146 U-Net architecture, renowned for its efficacy in medical imaging tasks¹⁵⁻¹⁷. The overlying

147 nnU-Net framework then automatically configures its network architecture, preprocessing,
148 and training strategy based on the dataset's characteristics, optimising for performance,
149 without requiring manual hyperparameter tuning or architecture modifications from the user.

150

151 For the five different image features, we trained two separate nnU-net models. A single
152 multi-class model for disc, hyper-AF and hypo-AF, and ring, and a separate single-class
153 model for vessels. As with common practice for nn-Unet each model consisted of an
154 ensemble of five U-nets with identical architectures, but different weights, trained
155 independently and then ensembled at inference, taking the unweighted average of the
156 probability scores across networks.

157

158 The model was trained using a sum of Dice and cross-entropy loss functions to optimise for
159 multi-class segmentation accuracy. Hyperparameters, such as learning rate and batch size,
160 were selected by the nnU-Net based on its analysis of the dataset. Training was curtailed at
161 200 epochs as this was sufficient to achieve convergence in most cases.

162

163 Validation of AIRDetect Segmentation Model

164 Model validation was assessed using the Dice coefficient between the model predictions and
165 the corresponding grader annotation on the hold-out test set. Where images were double
166 graded, we took the mean of the model-grader Dice for each grading. We also analysed the
167 accuracy of the model-grader agreement for simple presence/absence detection where we
168 counted cases as positive for which the model/annotator marked at least some part of the
169 image for the given feature, and negative otherwise, from which we derived
170 presence/absence detection accuracy, precision and recall.

171 Automatic Annotations on Real World IRD Dataset

172 The trained models were applied to automatically segment 45,749 FAF images (55-degree)
173 from 3,606 IRD patients with a molecularly confirmed diagnosis from MEH covering 170
174 genes^{2,11}. Images where the optic disc was not segmented by the model were removed, as
175 these images were of poor quality or not centred on the macula (**Supplementary Figure 2**).
176 Results were analysed from 33,042 FAF images from 3,496 patients, after filtering.

177

178 For each of the generated masks we extracted: a) if the feature was present or absent; b)
179 the area, number of pixels in the segmented mask multiplied by the resolution; c) the number
180 of connected components, found using watershed clustering¹⁸; d) feature brightness, mean
181 intensity of pixels from the region covered by the segmented mask. For vessels, we

182 calculated a selection of metrics defined in **Supplementary Table 2**, using the provided
183 code from the reti-py library as used in the AutoMorph repository ¹⁹. Features were also
184 analysed based on their distance from the fovea.

185

186 To calculate rate of progression for a given feature, a linear regression was fit to each
187 patient-eye, taking time since the first appointment (in years) as the independent variable,
188 and taking the calculated areas of the segmented feature at each time-point as the
189 measured variable. The slope of the regression was then averaged across eyes per-patient
190 to give a rate of progression. Where multiple scans per eye were present for a given date,
191 we took the most recent scan with the rationale that good quality scans were less likely to
192 lead to further imaging by the operator.


193

194 Results

195 AIRDetect Model Validation

196

197 Examples of AIRDetect segmentation output are presented in **Figure 1**. Model-grader Dice
198 scores for disc, hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68



199 and 0.65, with intergrader Dice scores of 0.82, 0.75, 0.72, 0.80, 0.95, respectively. Model
200 detection accuracy ranged from 77% to 83% (excluding anatomical features) (**Table 2**).
201 Features which were the most challenging to detect were hyper-AF and ring as those had
202 the lowest precision scores at 0.53 and 0.60 respectively.

203 **Figure 1:** Examples of manually and automatically segmented masks for the five features: vessels,
204 disc, ring, hyper- and hypo-autofluorescence. The vessel dataset was separate to the rest of the data,
205 so vessel visualisation is separate from other features.
206
207
208

209 **Table 2:** Segmentation model training data and results. Dice score quantifies the model's
 210 segmentation performance and presence/absence quantifies its feature detection performance. Total
 211 = number of annotated images. Incidence = percent of images with gradable feature. Dice inter-grader
 212 = inter-grader agreement of double-graded images (repeated from **Table 2** for reference). Dice model-
 213 grader = Dice score between model and graders, with mean scores used when images were double-
 214 graded.

| Feature | Train set | | Test Set | | Segmentation (Dice) | | Detection (Presence/Absence) | | |
|----------|-----------|-----------|----------|-----------|---------------------|--------------|------------------------------|-----------|--------|
| | Total | Incidence | Total | Incidence | Inter-grader | Model-grader | Accuracy | Precision | Recall |
| disc | 506 | 98% | 48 | 98% | 0.82 | 0.86 | - | - | - |
| hypo-AF | 506 | 70% | 48 | 44% | 0.75 | 0.72 | 83.3% | 0.81 | 0.81 |
| hyper-AF | 506 | 18% | 48 | 23% | 0.72 | 0.69 | 79.2% | 0.53 | 0.82 |
| ring | 506 | 32% | 48 | 31% | 0.80 | 0.68 | 77.1% | 0.60 | 0.80 |
| vessels | 72 | 100% | 23 | 100% | 0.94 | 0.65 | - | - | - |


215

216 Gene-phenotype Associations

217

218 Analysing associations between identified features and genes across most common genes
 219 (**Supplementary Table 3**), the five genes with the largest hypo-AF areas were *CHM*,
 220 *ABCC6*, *ABCA4*, *RDH12*, and *RPE65*, with mean per-patient areas of 41.5, 30.0, 21.9, 21.4,
 221 and 15.1 mm² (**Figure 2a**). The five genes with the largest hyper-AF areas were *BEST1*,
 222 *CDH23*, *RDH12*, *MYO7A*, and *NR2E3*, with mean areas of 0.49, 0.45, 0.44, 0.39, and 0.34
 223 mm² respectively (**Figure 2b**). The five genes with largest ring areas were *CDH23*, *NR2E3*,
 224 *CRX*, *EYS* and *MYO7A*, with mean areas of 3.63, 3.32, 2.84, 2.39, and 2.16 mm² (**Figure**
 225 **2c**). At the gene variant level, considering the p.(Gly1961Glu) *ABCA4* variant showed a
 226 higher ring area than the other common *ABCA4* variants (**Supplementary Figure 4**). Vessel
 227 density was found to be highest in *EFEMP1*, *BEST1*, *TIMP3*, *RS1*, and *PRPH2* (10.6%,
 228 10.3%, 9.8%, 9.7%, 8.9%) and was lower in Retinitis Pigmentosa (RP) and Leber Congenital
 229 Amaurosis associated genes (**Figure 2d**). A full breakdown of features across the 30 most
 230 common genes is given in **Supplementary Table 3**, for all genes in **Supplementary Table**
 231 **4** and for vessels in **Supplementary Table 5**.


232



233
 234 **Figure 2:** Mean **a)** extent of hypo-AF, **b)** extent of hyper-AF, **c)** extent of ring, and, **d)** Vessel density
 235 (ratio between area of vessels and total image area) across the 30 most common genes (*RPE65*
 236 included for reference). Error bars denote standard error. Values were first averaged by patient before
 237 averaging by gene to minimise correlations due to multiple contributions from individual patients.
 238 Genes are grouped into approximate phenotype groupings denoted by bar styling.
 239

240 We analysed how features vary with distance from the fovea by looking at the prevalence of
 241 each feature in each 0.5 mm annulus moving away from the fovea. **Figure 3** compares
 242 prevalence of hyper- and hypo-AF at different distances from the fovea in five different
 243 genes (see **Supplementary Figure 7** for scale). The two genes associated largely with
 244 maculopathy or cone-rod dystrophy (*ABCA4*, *PRPH2*) show increased hypo-AF at the fovea
 245 (**Figure 3.a** and **Figure 2.a**) but reducing proportions of the retina displaying hypo-AF
 246 moving away from the fovea. The two RP associated genes (*USH2A*, *RPGR*) show less
 247 hypo-AF across the whole retina compared with the cone-rod genes, but with a bimodal
 248 profile, with the greatest relative proportion of hypo-AF at the fovea followed by 4-6mm from
 249 the fovea, just within the vascular arcade. For *CHM*, unlike the other genes, there was the
 250 least hypo-AF at the fovea, but substantially increased hypo-AF away from the fovea. For
 251 hyper-AF there is an increased proportion of hyper-AF at the fovea in all genes except
 252 *ABCA4* that reduces further from the fovea (**Figure 3b**). In the two RP associated genes
 253 (*USH2A*, *RPGR*) there is an increase in hyper-AF at 1-3mm from the fovea.


254



255

256 **Figure 3:** Autofluorescence (AF) as a proportion of total altered AF area in the image compared with
 257 distance from fovea for patients with variants in *ABCA4*, *RPGR*, *USH2A*, *RPGR*, and *CHM* for a)
 258 hypo-AF and b) hyper-AF.
 259

260 In **Figure 4** the area of hyper-AF within 1.5mm of the fovea is compared against patient age
 261 for five different IRD genes. Most genes showed an increase with age, with the exception of
 262 *PRPH2*, which remained fairly stationary, and *BEST1*, which demonstrated a sharp
 263 decrease with patient age - although there was a considerable variability across ages within
 264 all genes.
 265



266

267 **Figure 4:** hyper-AF area within 1.5mm of the fovea (corresponding to inner 3mm ETDRs ring)
 268 compared with patient age. Least-squares regression line in red. Significant increase in hyper-AF with
 269 age for *ABCA4* ($\beta=691 \mu\text{m}^2/\text{yr}$, $p<0.001$), *USH2A* ($\beta=4090 \mu\text{m}^2/\text{yr}$, $p<0.001$) and *RPGR*
 270 ($\beta=2520 \mu\text{m}^2/\text{yr}$, $p<0.029$). Significant decrease for *BEST1* ($\beta=-6500 \mu\text{m}^2/\text{yr}$, $p<0.001$). No significant
 271 changes of hyper-AF with age were found for *PRPH2*.
 272
 273
 274
 275

276


277 Disease Progression

278 We applied AIRDetect longitudinally to monitor progression within individual patients across
279 multiple visits. **Figure 5** shows an example using AIRDetect to visualise the decrease in ring
280 area in individual patients with RP associated with variants in four different genes, namely
281 *USH2A*, *PRPH2*, *RHO* and *EYS*. Comparing these four RP genes in the entire MEH IRD
282 cohort, average rate of decrease in total ring area was greater in patients with RP associated
283 with *EYS* ($-0.178 \text{ mm}^2/\text{year}$), *USH2A* ($-0.066 \text{ mm}^2/\text{year}$), and *RPGR* ($-0.046 \text{ mm}^2/\text{year}$), when
284 compared to *RHO* ($-0.040 \text{ mm}^2/\text{year}$).

285

286 We also applied AIRDetect to monitor progression in patients belonging to three subgroups
287 of *ABCA4* (**Figure 6**). Patients were classified into three groups (A, B and C) based on
288 increasing severity of genetic variants as defined by Cornelis et al.^{20,21}. Patients in group A
289 had two severe variants, while group C had a mild variant in trans with any other variant.
290 Patients with variants of known severity whose combination do not fit the other two groups
291 were placed into group B. The average increase in hypo-AF area per year was compared
292 between groups (**Supplementary Figure 3**). In keeping with previous studies^{22–26}, the mean
293 per-patient rate of increase in hypo-AF area was highest in the highest severity classification
294 (group A), at $3.11 \text{ mm}^2/\text{year}$, followed by $1.59 \text{ mm}^2/\text{year}$ for the intermediate severity group
295 (B), and finally $0.87 \text{ mm}^2/\text{year}$ in the lowest severity group (C) (**Supplementary Table 6**).


296



297

298 **Figure 5:** Automatic monitoring of lesion size for disease progression. Decreasing area of ring for four
299 patients with disease-causing variants in: a) *RPGR*, b) *USH2A*, c) *RHO*, and d) *EYS*. In these genes,
300 the macular ring is expected to shrink in diameter over time as the disease progresses.

301



302
303
304
305

Figure 6: Increasing area of hypo-af for two patients of each of the three *ABCA4* severity groups: a) group A, b) group B and c) group C. Here we see the expected patterns of progression reported in **Supplementary Table 6** with A being the fast progressors, followed by B and C.

306 Discussion

307 The results of our cross-sectional analysis match known genotype-phenotype associations
308 demonstrating the validity of our approach, as well yielding novel insights. For example in
309 **Figure 2.a**, *CHM* and *ABCA4* both exhibited higher levels of hypo-AF, consistent with the
310 large areas of atrophy that spare the fovea in choroideremia, as well as the macular atrophy
311 typically seen in STGD1 disease (*ABCA4*)^{7,27-29}. Of interest however, *ABCC6* which is
312 associated with pseudoxanthoma elasticum was identified to have second largest areas of
313 hypo-AF. On further inspection, can be explained by the large angioid streaks characteristic
314 of this condition which can appear as hypo-AF on FAF³⁰. For hyper-AF, *BEST1* exhibited the
315 largest areas of hyper-AF, which can be attributed to the vitelliform lesion(s) that are
316 characteristically observed in autosomal dominant and recessive forms of the disease³¹⁻³³
317 (**Figure 2.b**). For ring the presence of a macular ring typically corresponds to a demarcation
318 between diseased and non-diseased retina, and is usually seen in RP and cone rod
319 dystrophies, in keeping with our findings herein³ (**Figure 2.c**). The lower vessel density
320 observed in RP and LCA genes was also in keeping with the vessel attenuation commonly
321 associated with these genes^{34,35} (**Figure 2.d**). As well as gene-phenotype associations, we
322 also found associations at the individual variant level confirming known association between
323 the p.(Gly1961Glu) variant in *ABCA4* and presence of a macular ring³⁶⁻³⁹ (**Supplementary**
324 **Figure 3**). When considering feature prevalence from the fovea, we found, as expected, that
325 genes usually associated with cone-rod degeneration showed a decrease in hypo-AF extent
326 moving away from the fovea, but with an opposite trend for the RP genes and *CHM* (**Figure**
327 **3**). Hyper-AF was mainly concentrated at the fovea, but with a distinctive peak at 2-3mm
328 from the fovea which may be attributed to partial macular rings classified as hyper-AF by our
329 model (**Figure 3.b**). *PRPH2* also had a higher coverage of hyper-AF in the fovea when
330 compared to *ABCA4* which is consistent with the pattern/macular dystrophy and adult
331 vitelliform phenotypes associated with *PRPH2*⁴⁰ (**Figure 3.b**).

332
333 In our longitudinal analysis we were able to replicate the findings of Fakin *et al.* 2016 in
334 **Figure 7** and **Table 4**, where we found that growth of areas of hypo-AF was much more
335 rapid in the group associated with more severe *ABCA4* genetic variants²². Our estimates for
336 rate of progression were higher than that previously reported, which may be due to the use
337 of 55-degree as opposed to 30-degree imaging in our dataset and hence a larger area of
338 hypo-AF^{25,41}. Comparing hyper-AF across patient age in **Figure 4**, the hyper-AF within
339 1.5mm of the fovea increased for *ABCA4*, *USH2A* and *RPGR*, consistent with lesions
340 developing with disease progression over time. However, there were some noteworthy
341 exceptions for individual genes. In particular, *BEST1* is associated with “yolk-like” regions of
342 hyper-AF, typically within 2-3mm of the perifovea, which change over time through pre-

343 vitelliform, vitelliform, pseudohypopyon, vitelliruptive stages and finally to the atrophic stage
344 ^{3,33}. The highest hyper-AF signal would be associated with the vitelliform stage, progressively
345 reducing in intensity to become a region of hypo-AF by the atrophic stage, which matches
346 what we see as a decrease in foveal hyper-AF with age. No significant progression of
347 hyper-AF with age was detected for *PRPH2* which is likely due to the later onset of the
348 condition in most patients (typically after 45 years of age) and hence the limited age range in
349 our cohort , as well as the milder pattern of dystrophy ⁴²

350

351 We also identified increased rate of decrease in area of macular ring in *EYS*, *USH2A* and
352 *RPGR* compared to *RHO* (**Figure 6**). Monitoring the rate in which the macular ring narrows
353 down is common practice in generalised retinal dystrophies such as RP ⁵. A more rapid
354 encroachment of the macular ring in autosomal recessive (*USH2A*, *EYS*) and X-linked
355 (*RPGR*) genes compared to the autosomal dominant *RHO*, is consistent with the latter
356 having a slower disease progression compared to the others ⁴³.

357

358 To date, deep learning AI models to analyse FAF images from IRD patients have been
359 limited. There have been studies developing classification models of FAF images based on
360 IRD phenotypes ⁴⁴⁻⁴⁷. But as to segmentation approaches, areas of hypo-AF have been
361 measured either manually or semi-automatically using RegionFinder on HEYEX2 software
362 to study the progression rate of the area of atrophy in STGD1 disease ⁴⁸⁻⁵¹. These
363 approaches compared to deep-learning approaches would be challenging to scale
364 accurately to our real-world dataset as they require considerable parameter tuning compared
365 to deep-learning based approaches such as AIRDetect. Previous deep-learning based
366 segmentation approaches have mostly focused on STGD1 to segment for hypo-AF⁵² or
367 flecks¹⁰. Hence our AIRDetect approach represents the first to be developed and applied to
368 a wide range of IRDs covering 170 genes.

369

370 One limitation of our approach is that the gene associations described in our study are
371 limited by the variation in phenotypes which can occur with different variants in the same
372 gene or different modes of inheritance. For example, *CRX* can be associated with a mild
373 CORD but also quite severe LCA ⁵³⁻⁵⁵. *RPGR* can be associated with RP, LCA, macular
374 dystrophy and CORD ^{56,57}. We conducted a sub analysis in *ABCA4* (**Supplementary Figure**
375 **4**) but have not yet conducted this analysis across all gene variants and modes of
376 inheritance.

377

378 Another limitation is the large variance in imaging quality in our real-world dataset, which
379 affects the reliability of some of the features in lower quality images. While automatic image
380 quality assessment tools exist for colour fundus retinal imaging ⁵⁸, none have been

381 developed for FAF imaging. Assessing image quality can also be particularly challenging for
382 IRDs as they are associated with a wide range of pathologies, many of which can affect
383 perceived image quality, as well as make it more challenging for the operator to acquire
384 good quality images. We plan to develop an IRD FAF image quality assessment model in
385 future, which should help to improve the consistency of our segmented masks and reduce
386 noise in our analysis.

387

388 We anticipate that AIRDetect can be used to validate further clinically relevant findings, as
389 well as identifying new potential associations between different feature patterns and certain
390 genes or variants. Our approach could also be applied to identifying structure-function
391 association (**Supplementary Figure 5**) as well as cross-modality image registration tasks by
392 using vessel-based segmentation to align images (**Supplementary Figure 6**). Besides
393 IRDs, the diverse nature of IRD-associated pathologies might make AIRDetect useful to
394 improve robustness for segmentation of FAF imaging for other non-IRD conditions or provide
395 a good starting point for developing models for specific conditions where data is more scarce
396 or to other imaging modalities such as ultra-widefield imaging, via transfer learning.

397

398 In conclusion, we have conducted, to our knowledge, the largest quantitative cross-sectional
399 and longitudinal analysis of FAF features across a diverse range of IRDs in a real world
400 dataset, enabled by our novel automatic segmentation AI model, AIRDetect.

401 Ethics

402 This research was approved by the IRB and the UK Health Research Authority Research
403 Ethics Committee (REC) reference (22/WA/0049) “Eye2Gene: accelerating the diagnosis of
404 inherited retinal diseases” Integrated Research Application System (IRAS) (project ID:
405 242050). All research adhered to the tenets of the Declaration of Helsinki.

406

407 Code availability

408 The source code for the AIRDetect model architecture training and inference is available
409 from <https://github.com/Eye2Gene/>. The model weights of AIRDetect are intellectual
410 proprietary of UCLB so cannot be shared publicly. However, they may be shared via a
411 licensing agreement with UCLB. A running version of the AIRDetect app is accessible via the
412 Eye2Gene website (www.eye2gene.com) and via the Moorfields Grading Portal
413 (grading.readingcentre.org) on invitation.

414

415 Data availability

416 The data that support the findings of this study are divided into two groups, published data
417 and restricted data. Published data are available from the Github repository. Restricted data
418 are curated for AIRDetect users under a license and cannot be published, to protect patient
419 privacy and intellectual property. Synthetic data derived from the test data has been made
420 available at <https://github.com/Eye2Gene/>.

421

422 Author contributions

423 WAW analysed the data and wrote the manuscript. NP designed the obtained the funding,
424 designed the experiments, analysed data and wrote the manuscript. MM, KB, WAW, TACG,
425 SAK, MDV, BM designed the experiments, analysed data and wrote the manuscript. SS
426 analysed the data. MS wrote the manuscript. PBa analysed the data. PBU, DP analysed the
427 data. All authors have critically reviewed the manuscript.


428 Acknowledgement

429 This work is primarily funded by a NIHR AI Award (AI_AWARD02488) which supported NP,
430 WAW, MM, KB, SD and SM. The research was also supported by a grant from the National
431 Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Moorfields Eye
432 Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. NP was also previously
433 funded by Moorfields Eye Charity Career Development Award (R190031A). BJ was partially
434 funded by IIR-DE-002818 from Shire/Takeda and by the European Reference Network for
435 Rare Malformation Syndromes, Intellectual and Other Neurodevelopmental Disorders (ERN-
436 ITHACA). OAM is supported by the Wellcome Trust (206619/Z/17/Z). AYL is supported by
437 an unrestricted and career development award from RPB, Latham Vision Science Awards,
438 NIH OT2OD032644, NEI/NIH K23EY029246, and NIA/NIH U19AG066567. SA is supported
439 by a scholarship from Qatar National Research Fund (GSRA6-1-0329-19010). This project
440 was also supported by a generous donation by Stephen and Elizabeth Archer in memory of
441 Marion Woods. The hardware used for analysis was supported by the BRC Challenge Fund
442 (BRC3_027). We also gratefully acknowledge the support of NVIDIA Corporation with the
443 donation of the Titan Xp GPU used for this research. The views expressed are those of the
444 authors and not the funding organisations.

445


446 Supplementary

447 **Supplementary Figure 1:** Data flowchart with number of images, patients, eyes, and genes at each
 448 stage of AIRDetect model development.



449
 450
 451

452 **Supplementary Figure 2:** Examples of images with no Disc segmentation from the model. These are
453 either poor quality, have significant atrophy, or are improperly centred.
454



455
456

457 **Supplementary Table 1:** Overview of annotated dataset for the manually segmented features,
 458 considering each feature individually. Not all features were gradable within all images, with some
 459 images only annotated for some features. Images for vessel annotations were selected by clinicians
 460 and were all gradable. Incidence includes ungradable

| Feature | Graded | Double graded | Partially Gradable | Un-Gradable | Num Patients | Num Genes | Present | Incidence |
|----------|--------|---------------|--------------------|-------------|--------------|-----------|---------|-----------|
| disc | 736 | 207 | 74 | 32 | 573 | 63 | 716 | 97.3% |
| hypo-AF | 736 | 204 | 75 | 32 | 573 | 63 | 482 | 65.5% |
| hyper-AF | 730 | 191 | 77 | 32 | 570 | 63 | 106 | 14.5% |
| ring | 729 | 195 | 76 | 32 | 571 | 63 | 212 | 29.1% |
| vessels | 206 | 13 | <i>n/a</i> | <i>n/a</i> | 127 | 33 | 206 | 100% |

461
 462
 463

Supplementary Table 2: Vessel metrics and their description.

| Vessel Metric | Description |
|------------------------------|--|
| Fractal Dimension | Method that represents geometric complexity of the vascular branching pattern observed in the retina. Essentially how close are the vessels to being “space-filling”. |
| Vessel Density | Ratio between area of vessels and total image area. |
| Average Width | Average width of vessels. |
| Distance Tortuosity | Distance tortuosity is a measure of the tortuosity of a path based on the ratio of the actual path length to the straight-line distance between the start and end points of the path ⁵⁹ |
| Squared Curvature Tortuosity | Squared curvature tortuosity is a more sophisticated measure of tortuosity that takes into account the curvature along the path, providing a detailed view of its winding nature ⁵⁹ |
| Tortuosity Density | Assesses vessel tortuosity by aggregating local contributions, examining the degree to which each turn curve deviates from a smooth curve ⁶⁰ |

464
 465

Supplementary Table 3: Feature statistics by gene for selected genes. Results are mean across all images. %=Incidence, A=Average Area (mm²), C=Num Components, I = Intensity (pixel brightness), <3mm=Proportion of feature area within 3mm of the fovea (corresponding to outer 6mm ETRDS ring), D=vessel density, F=fractal dimension. The table cells have been shaded with lower values in red, intermediate values in white and larger values in green.

| Gene | disc | | | | hypo-AF | | | | | hyper-AF | | | | | ring | | | | | vessels | |
|---------|------|------|--------|--------|---------|-------|------|--------|--------|----------|------|------|--------|--------|--------|------|------|--------|--------|---------|------|
| | A | C | I | <3mm | % | A | C | I | <3mm | % | A | C | I | <3mm | % | A | C | I | <3mm | D | F |
| ABCA4 | 2.19 | 1.01 | 9.20% | 13.70% | 80.30% | 19.81 | 1.45 | 11.10% | 61.30% | 18.00% | 0.05 | 0.33 | 66.40% | 48.30% | 33.50% | 0.57 | 1.58 | 59.60% | 81.80% | 7.65% | 1.33 |
| ABCC6 | 1.53 | 1.03 | 16.90% | 17.60% | 69.00% | 21.44 | 2.08 | 14.30% | 32.60% | 54.90% | 0.23 | 1.2 | 62.50% | 23.40% | 8.20% | 0.03 | 0.15 | 43.30% | 38.00% | 8.07% | 1.37 |
| BBS1 | 2.59 | 1.02 | 10.40% | 7.50% | 67.50% | 8.35 | 1.29 | 11.90% | 56.90% | 25.90% | 0.15 | 0.38 | 47.30% | 86.90% | 32.50% | 0.84 | 1.03 | 56.50% | 72.70% | 4.56% | 1.18 |
| BEST1 | 1.84 | 1.01 | 11.60% | 4.10% | 40.50% | 2.58 | 0.9 | 11.50% | 59.70% | 57.50% | 0.73 | 1.09 | 61.20% | 59.80% | 57.50% | 1.28 | 1.83 | 56.30% | 77.20% | 9.62% | 1.38 |
| CACNA1F | 2.04 | 1.01 | 14.80% | 0.00% | 5.70% | 0.91 | 0.2 | 7.10% | 42.40% | 12.80% | 0.01 | 0.15 | 59.80% | 2.50% | 3.80% | 0.01 | 0.06 | 53.60% | 79.80% | 5.35% | 1.21 |
| CDH23 | 2.05 | 1.01 | 14.30% | 6.40% | 16.20% | 0.71 | 0.47 | 10.40% | 42.00% | 19.60% | 0.23 | 0.5 | 57.60% | 34.20% | 77.30% | 2.46 | 2.73 | 47.30% | 67.30% | 2.46% | 1.05 |
| CERKL | 2.63 | 1 | 12.30% | 9.10% | 82.30% | 10.33 | 1.43 | 12.10% | 51.70% | 17.70% | 0.02 | 0.21 | 46.00% | 88.60% | 29.70% | 1.04 | 0.95 | 58.10% | 65.30% | 3.51% | 1.16 |
| CHM | 1.45 | 1.06 | 20.60% | 2.80% | 82.60% | 51.77 | 3.28 | 19.90% | 21.00% | 48.80% | 0.26 | 0.83 | 54.50% | 37.90% | 5.50% | 0.03 | 0.08 | 43.20% | 32.20% | 6.20% | 1.3 |
| CNGA3 | 1.74 | 1.01 | 13.80% | 14.50% | 31.10% | 1.48 | 0.96 | 7.10% | 56.30% | 8.00% | 0.05 | 0.17 | 54.00% | 31.80% | 35.60% | 0.32 | 0.75 | 50.00% | 74.90% | 5.36% | 1.1 |
| CNGB3 | 1.91 | 0.99 | 14.90% | 12.70% | 12.50% | 0.16 | 0.38 | 6.70% | 73.60% | 10.40% | 0.01 | 0.12 | 52.70% | 63.90% | 32.60% | 0.2 | 0.63 | 54.60% | 92.20% | 5.92% | 1.1 |
| CRB1 | 1.97 | 1.02 | 14.70% | 3.60% | 55.20% | 8.3 | 1.22 | 15.60% | 40.40% | 44.00% | 0.41 | 0.89 | 46.40% | 54.00% | 43.70% | 1.73 | 1.35 | 48.90% | 59.20% | 4.27% | 1.1 |
| CRX | 2.11 | 1 | 15.60% | 5.70% | 70.30% | 5.51 | 1.39 | 15.60% | 62.70% | 16.90% | 0.05 | 0.26 | 50.70% | 29.90% | 59.30% | 2.23 | 4.22 | 52.90% | 65.90% | 7.30% | 1.1 |
| EFEMP1 | 1.77 | 1 | 15.30% | 6.00% | 78.70% | 5.15 | 1.84 | 14.20% | 82.40% | 77.90% | 0.24 | 1.55 | 61.80% | 79.40% | 24.10% | 0.18 | 0.66 | 60.00% | 82.50% | 10.10% | 1.1 |
| EYS | 2.36 | 1.02 | 15.20% | 2.90% | 65.90% | 9.55 | 1.64 | 13.30% | 27.30% | 23.40% | 0.23 | 0.4 | 57.60% | 42.90% | 72.50% | 2.08 | 2.76 | 52.60% | 76.80% | 3.07% | 1.1 |
| GUCY2D | 2 | 1 | 14.70% | 6.50% | 48.00% | 5.25 | 0.86 | 17.50% | 71.20% | 17.60% | 0.22 | 0.3 | 61.20% | 36.00% | 60.90% | 1.51 | 2.94 | 53.10% | 75.00% | 6.91% | 1.1 |
| MYO7A | 2.07 | 0.99 | 15.80% | 2.30% | 42.30% | 2.37 | 0.95 | 18.00% | 32.90% | 28.00% | 0.41 | 0.97 | 53.70% | 21.80% | 73.60% | 3.24 | 3.26 | 47.00% | 57.80% | 2.70% | 1.1 |
| NR2E3 | 1.94 | 1.02 | 10.90% | 7.40% | 31.50% | 1.42 | 0.76 | 10.20% | 12.90% | 21.40% | 0.37 | 0.5 | 56.50% | 17.90% | 39.60% | 1.72 | 1.4 | 52.20% | 24.70% | 8.33% | 1.1 |
| PDE6B | 2.62 | 1.01 | 14.80% | 3.40% | 52.20% | 4.48 | 0.93 | 17.00% | 49.30% | 21.30% | 0.08 | 0.28 | 55.10% | 56.90% | 86.00% | 3.37 | 4.06 | 47.30% | 86.60% | 3.00% | 1.1 |
| PROM1 | 2.3 | 1.01 | 12.60% | 7.00% | 80.00% | 12.15 | 1.72 | 12.60% | 72.00% | 21.10% | 0.04 | 0.25 | 52.30% | 72.90% | 34.80% | 0.85 | 2.06 | 54.00% | 82.50% | 6.10% | 1.1 |
| PRPF31 | 2.2 | 1.03 | 15.50% | 1.20% | 48.10% | 6.78 | 1.56 | 12.00% | 41.30% | 18.80% | 0.12 | 0.34 | 45.90% | 68.30% | 64.00% | 2.17 | 2.85 | 52.50% | 86.90% | 4.10% | 1.1 |
| PRPH2 | 2.05 | 1.01 | 12.30% | 4.50% | 68.70% | 10.28 | 1.89 | 10.10% | 62.00% | 36.40% | 0.07 | 0.58 | 59.10% | 77.10% | 26.30% | 0.69 | 0.85 | 55.80% | 69.40% | 8.00% | 1.1 |
| RDH12 | 1.92 | 1.01 | 18.00% | 11.80% | 58.10% | 22.35 | 1.1 | 19.00% | 37.30% | 33.70% | 0.37 | 0.52 | 49.00% | 22.10% | 34.10% | 1.51 | 2.52 | 57.90% | 84.80% | 2.93% | 0.9 |
| RHO | 2.17 | 1.03 | 15.50% | 1.50% | 61.90% | 9.74 | 1.72 | 13.60% | 34.80% | 18.50% | 0.11 | 0.24 | 53.00% | 56.00% | 70.60% | 2.25 | 2.99 | 53.60% | 82.80% | 4.47% | 1.1 |
| RP1 | 2.19 | 1.01 | 13.70% | 5.50% | 63.00% | 9.32 | 1.76 | 13.10% | 40.10% | 19.10% | 0.18 | 0.27 | 55.90% | 66.70% | 65.00% | 2.03 | 2.98 | 54.60% | 74.80% | 4.59% | 1.1 |
| RP2 | 2.48 | 1.05 | 9.90% | 13.30% | 47.60% | 3.1 | 1.19 | 10.50% | 48.30% | 6.90% | 0.02 | 0.08 | 54.70% | 84.40% | 13.00% | 0.26 | 0.38 | 59.00% | 67.80% | 3.65% | 1.1 |
| RPE65 | 1.15 | 1.06 | 19.30% | 7.60% | 52.40% | 40.13 | 2.65 | 15.00% | 29.10% | 37.80% | 0.24 | 0.65 | 56.40% | 61.80% | 4.90% | 0.19 | 0.05 | 43.10% | 97.60% | 2.04% | 0.97 |
| RPGR | 2.31 | 1.01 | 13.70% | 3.70% | 54.20% | 7.78 | 1.27 | 14.40% | 36.50% | 22.60% | 0.13 | 0.31 | 54.40% | 58.60% | 61.30% | 2.13 | 2.09 | 55.90% | 82.00% | 4.06% | 1.19 |
| RS1 | 1.93 | 1 | 11.90% | 3.50% | 26.80% | 2.41 | 0.58 | 10.70% | 36.70% | 24.80% | 0.1 | 0.37 | 44.30% | 73.20% | 16.90% | 0.35 | 0.59 | 53.00% | 66.40% | 8.69% | 1.34 |
| TIMP3 | 1.71 | 1.01 | 17.50% | 9.50% | 62.10% | 16.35 | 1.84 | 15.30% | 46.50% | 30.70% | 0.14 | 0.51 | 58.50% | 32.60% | 27.00% | 0.47 | 1 | 55.20% | 35.30% | 9.15% | 1.39 |
| USH2A | 2.17 | 1.02 | 15.60% | 2.30% | 61.30% | 8.47 | 1.76 | 13.00% | 36.50% | 19.80% | 0.15 | 0.31 | 53.50% | 66.50% | 72.10% | 1.98 | 3.2 | 53.50% | 87.50% | 3.42% | 1.17 |
| All | 2.09 | 1.02 | 13.50% | 6.90% | 61.20% | 13.04 | 1.46 | 13.00% | 48.20% | 25.10% | 0.15 | 0.43 | 57.10% | 52.80% | 43.70% | 1.19 | 1.78 | 54.10% | 77.90% | 5.75% | 1.25 |

medRxiv preprint doi: <https://doi.org/10.1101/2024.03.24.24304809>; this version posted March 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary Table 4: Feature statistics for all genes. Phenotypes: pheno = most common phenotype presentation according to literature. ACHM = achromatopsia, ALB = albinism, BEST = best disease, CD = cone-dystrophy, CHM = choroidemia, CR = cone-rod, CSNB = congenital stationary night blindness, DR = diabetic retinopathy, FEVR = Familial exudative vitreoretinopathy, GA = Gyrate atrophy, LCA = Leber's congenital amaurosis, MAC = Microphthalmia, anophthalmia, coloboma, MD = macular dystrophy, OA = optic atrophy, PD = pattern dystrophy, PXE = pseudoxanthoma elasticum, RP = retinitis pigmentosa. pat = number of patients. img = number of FAF images. Feature metrics are averaged across all images per gene. Features: % = average incidence in percent, A = average area in mm², C = average number of clusters, I = average pixel intensity in percentage, % <6mm = average incidence within 6mm area in percent, FD = vessel fractal dimensions, D = average vessel density, W = average vessel width, DTM = distance tortuosity mean, SCTM = squared curvature tortuosity mean, TDM = tortuosity density mean.

| gene | pheno | pat | img | disc | | | | hypo-AF | | | | hyper-AF | | | | ring | | | | vessels | | | | | | | | |
|----------|-------|-----|------|------|------|--------|--------|---------|-------|------|--------|----------|--------|------|------|--------|--------|--------|------|---------|--------|---------|------|------|--------|-------|---------|------|
| | | | | A | C | I | % <6mm | % | A | C | I | % <6mm | % | A | C | I | % <6mm | % | A | C | I | % <6mm | FD | D | W | DTM | SCTM | TDM |
| ABCA4 | CR | 873 | 7926 | 2.19 | 1.01 | 9.25% | 13.74% | 80.29% | 19.81 | 1.45 | 11.13% | 61.34% | 18.04% | 0.05 | 0.33 | 66.40% | 48.28% | 33.46% | 0.57 | 1.58 | 59.62% | 81.76% | 1.33 | 0.08 | 184.81 | 4.81 | 61.64 | 0.71 |
| ABCC6 | PXE | 17 | 268 | 1.53 | 1.03 | 16.85% | 17.58% | 69.03% | 21.44 | 2.08 | 14.31% | 32.63% | 54.85% | 0.23 | 1.20 | 62.52% | 23.36% | 8.21% | 0.03 | 0.15 | 43.31% | 38.00% | 1.37 | 0.08 | 196.68 | 6.17 | 80.72 | 0.73 |
| ABHD12 | RP | 4 | 44 | 2.50 | 1.00 | 11.17% | 3.83% | 77.27% | 15.90 | 2.48 | 11.45% | 49.64% | 27.27% | 0.02 | 0.27 | 35.63% | 66.67% | 2.27% | 0.00 | 0.00 | 47.94% | 100.00% | 1.19 | 0.06 | 179.19 | 5.24 | 36.36 | 0.68 |
| ADAMTSL4 | | 1 | 12 | 2.27 | 1.00 | 11.05% | 0.00% | 25.00% | 0.02 | 0.33 | 9.49% | 0.00% | 0.00% | 0.00 | 0.00 | | | 16.67% | 0.03 | 0.17 | 42.55% | 100.00% | 1.35 | 0.07 | 213.39 | 4.03 | 53.32 | 0.69 |
| ADGRV1 | RP | 12 | 102 | 2.54 | 1.00 | 17.39% | 1.46% | 63.73% | 4.88 | 1.19 | 17.73% | 46.66% | 8.82% | 0.08 | 0.12 | 64.25% | 86.49% | 86.27% | 1.09 | 3.35 | 52.19% | 99.03% | 1.13 | 0.02 | 182.36 | 8.66 | 140.31 | 0.67 |
| AGBL5 | RP | 1 | 10 | 0.54 | 1.60 | 9.81% | 0.00% | 100.00% | 9.49 | 4.80 | 2.21% | 5.33% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.31 | 0.04 | 206.99 | 8.55 | 91.48 | 0.72 |
| AHI1 | RP | 6 | 49 | 2.85 | 1.00 | 10.99% | 5.88% | 65.31% | 12.24 | 0.86 | 12.82% | 53.64% | 10.20% | 0.01 | 0.06 | 42.02% | 60.00% | 42.86% | 0.50 | 0.96 | 54.65% | 85.91% | 1.14 | 0.03 | 180.38 | 5.46 | 58.98 | 0.70 |
| AIPL1 | CR | 2 | 25 | 2.48 | 1.00 | 9.60% | 0.06% | 8.00% | 0.11 | 0.40 | 2.85% | 2.66% | 32.00% | 0.03 | 0.24 | 47.47% | 0.00% | 80.00% | 8.66 | 2.12 | 40.42% | 41.64% | 1.12 | 0.04 | 229.54 | 5.70 | 40.85 | 0.71 |
| ALMS1 | CR | 1 | 11 | 2.36 | 1.00 | 13.89% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.10 | 0.04 | 186.00 | 5.01 | 67.32 | 0.70 |
| AMACR | RP | 2 | 12 | 1.69 | 1.00 | 18.99% | 0.00% | 41.67% | 0.10 | 0.42 | 13.05% | 77.46% | 66.67% | 0.10 | 0.67 | 56.90% | 3.57% | 25.00% | 0.09 | 0.33 | 43.51% | 75.00% | 1.15 | 0.04 | 191.50 | 7.62 | 110.12 | 0.65 |
| ARHGEF18 | RP | 3 | 39 | 2.34 | 1.00 | 15.63% | 1.72% | 46.15% | 2.88 | 1.13 | 11.33% | 6.43% | 33.33% | 0.12 | 0.69 | 41.63% | 58.53% | 56.41% | 0.99 | 2.08 | 48.92% | 48.09% | 1.22 | 0.05 | 201.54 | 8.35 | 48.53 | 0.64 |
| ARL3 | | 1 | 10 | 3.00 | 1.00 | 7.28% | 0.00% | 40.00% | 0.00 | 0.20 | 7.68% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.45 | 0.12 | 198.62 | 4.48 | 27.12 | 0.74 |
| ARL6 | RP | 2 | 14 | 1.93 | 1.00 | 21.11% | 22.91% | 92.86% | 35.47 | 1.43 | 16.59% | 46.02% | 50.00% | 0.23 | 0.57 | 43.28% | 85.71% | 0.00% | 0.00 | 0.00 | | | 0.89 | 0.00 | 123.00 | 25.43 | 1151.60 | 0.55 |
| ATF6 | ACHM | 2 | 15 | 2.00 | 1.00 | 17.23% | 0.55% | 53.33% | 2.88 | 0.53 | 13.46% | 81.15% | 46.67% | 0.03 | 0.53 | 55.29% | 38.45% | 13.33% | 0.02 | 0.13 | 29.13% | 100.00% | 1.28 | 0.06 | 229.27 | 4.11 | 47.41 | 0.75 |
| ATXN7 | CR | 1 | 9 | 1.44 | 1.00 | 18.74% | 0.00% | 22.22% | 0.14 | 0.78 | 0.50% | 100.00% | 55.56% | 0.05 | 1.22 | 64.87% | 0.00% | 0.00% | 0.00 | 0.00 | | | 1.36 | 0.08 | 243.18 | 10.45 | 149.14 | 0.73 |
| BBS1 | RP | 31 | 286 | 2.59 | 1.02 | 10.41% | 7.52% | 67.48% | 8.35 | 1.29 | 11.91% | 56.94% | 25.87% | 0.15 | 0.38 | 47.26% | 86.85% | 32.52% | 0.84 | 1.03 | 56.50% | 72.71% | 1.18 | 0.05 | 186.86 | 9.66 | 214.92 | 0.70 |
| BBS10 | RP | 4 | 35 | 2.47 | 1.09 | 12.38% | 30.85% | 91.43% | 8.64 | 1.37 | 11.18% | 41.65% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.96 | 0.01 | 172.29 | 13.56 | 349.29 | 0.68 |
| BBS12 | RP | 2 | 22 | 2.19 | 1.05 | 13.20% | 16.11% | 95.45% | 22.14 | 2.45 | 7.56% | 44.37% | 27.27% | 0.05 | 0.36 | 57.05% | 57.80% | 45.45% | 0.34 | 0.91 | 42.80% | 55.42% | 1.22 | 0.04 | 193.66 | 8.94 | 93.01 | 0.74 |
| BBS2 | RP | 2 | 14 | 2.96 | 1.00 | 7.20% | 19.31% | 100.00% | 4.91 | 1.50 | 14.15% | 76.73% | 0.00% | 0.00 | 0.00 | | | 57.14% | 1.85 | 1.43 | 63.87% | 89.38% | 1.29 | 0.04 | 134.42 | 6.12 | 201.98 | 0.74 |
| BBS5 | RP | 2 | 19 | 3.50 | 1.00 | 12.69% | 3.59% | 5.26% | 0.00 | 0.05 | 23.42% | 0.00% | 31.58% | 0.08 | 0.53 | 46.02% | 82.37% | 84.21% | 0.93 | 3.95 | 47.36% | 80.33% | 1.38 | 0.08 | 206.60 | 11.55 | 199.06 | 0.76 |
| BEST1 | BEST | 133 | 1461 | 1.84 | 1.01 | 11.59% | 4.14% | 40.45% | 2.58 | 0.90 | 11.50% | 59.70% | 57.49% | 0.73 | 1.09 | 61.18% | 59.81% | 57.49% | 1.28 | 1.83 | 56.31% | 77.22% | 1.38 | 0.10 | 203.18 | 4.46 | 49.43 | 0.71 |
| C1QTNF5 | RP | 10 | 73 | 1.85 | 1.00 | 13.85% | 3.18% | 78.08% | 27.18 | 1.93 | 15.97% | 23.12% | 8.22% | 0.01 | 0.07 | 59.98% | 50.00% | 1.37% | 0.02 | 0.07 | 51.84% | 100.00% | 1.35 | 0.08 | 199.82 | 4.78 | 43.26 | 0.73 |
| C21ORF2 | RP | 5 | 44 | 2.56 | 1.00 | 11.52% | 0.37% | 20.45% | 0.76 | 0.25 | 32.97% | 17.62% | 0.00% | 0.00 | 0.00 | | | 52.27% | 1.00 | 1.23 | 56.98% | 45.38% | 1.28 | 0.07 | 191.13 | 4.31 | 52.74 | 0.73 |
| C2ORF71 | RP | 10 | 85 | 2.38 | 1.01 | 13.39% | 6.76% | 96.47% | 19.08 | 1.75 | 12.65% | 65.48% | 7.06% | 0.00 | 0.07 | 55.40% | 83.33% | 23.53% | 0.63 | 0.86 | 62.86% | 62.54% | 1.05 | 0.03 | 177.08 | 13.59 | 252.66 | 0.63 |
| CABP4 | ACHM | 4 | 29 | 1.33 | 1.03 | 14.68% | 3.45% | 20.69% | 0.01 | 0.79 | 0.03% | 33.33% | 17.24% | 0.00 | 0.21 | 53.22% | 0.00% | 0.00% | 0.00 | 0.00 | | | 1.11 | 0.03 | 224.24 | 2.22 | 20.98 | 0.71 |
| CACNA1F | ACHM | 30 | 265 | 2.04 | 1.01 | 14.76% | 0.01% | 5.66% | 0.91 | 0.20 | 7.13% | 42.39% | 12.83% | 0.01 | 0.15 | 59.85% | 2.47% | 3.77% | 0.01 | 0.06 | 53.57% | 79.82% | 1.21 | 0.05 | 218.03 | 9.24 | 83.77 | 0.73 |
| CACNA2D4 | CR | 1 | 16 | 1.06 | 1.00 | 17.29% | 0.00% | 100.00% | 0.09 | 4.06 | 0.11% | 80.36% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.49 | 0.10 | 210.24 | 3.97 | 30.23 | 0.69 |
| CDH23 | RP | 17 | 260 | 2.05 | 1.01 | 14.31% | 6.45% | 16.15% | 0.71 | 0.47 | 10.44% | 41.97% | 19.62% | 0.23 | 0.50 | 57.64% | 34.17% | 77.31% | 2.46 | 2.73 | 47.34% | 67.30% | 1.05 | 0.02 | 198.91 | 7.97 | 177.84 | 0.68 |
| CDH3 | MD | 3 | 21 | 1.65 | 1.19 | 15.05% | 0.00% | 100.00% | 25.42 | 2.24 | 11.58% | 48.30% | 42.86% | 0.82 | 1.43 | 45.35% | 0.00% | 28.57% | 0.11 | 1.19 | 43.43% | 0.00% | 1.27 | 0.05 | 219.90 | 3.19 | 17.80 | 0.63 |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------|--------|-----|------|------|------|--------|--------|---------|-------|------|--------|---------|---------|------|------|--------|---------|---------|-------|------|--------|---------|------|------|--------|-------|--------|------|
| CDHR1 | RP | 18 | 144 | 2.48 | 1.04 | 12.55% | 5.10% | 80.56% | 7.39 | 1.71 | 11.82% | 66.14% | 22.92% | 0.18 | 0.26 | 49.52% | 75.30% | 36.81% | 1.11 | 1.25 | 53.78% | 70.56% | 1.22 | 0.04 | 180.64 | 7.80 | 77.75 | 0.68 |
| CEP290 | ACH | 16 | 166 | 2.22 | 0.99 | 14.25% | 3.10% | 19.88% | 0.90 | 0.69 | 6.43% | 48.94% | 13.25% | 0.10 | 0.25 | 62.19% | 13.64% | 70.48% | 1.40 | 2.10 | 54.86% | 80.08% | 1.16 | 0.04 | 186.46 | 10.90 | 281.31 | 0.71 |
| CEP78 | CR | 1 | 5 | 1.47 | 1.00 | 20.86% | 12.22% | 100.00% | 37.38 | 3.80 | 22.08% | 9.46% | 100.00% | 0.56 | 1.80 | 53.42% | 18.37% | 100.00% | 3.94 | 2.00 | 51.21% | 87.14% | 1.01 | 0.01 | 213.43 | 3.91 | 40.37 | 0.77 |
| CERKL | RP | 22 | 249 | 2.63 | 1.00 | 12.26% | 9.15% | 82.33% | 10.33 | 1.43 | 12.08% | 51.71% | 17.67% | 0.02 | 0.21 | 46.03% | 88.64% | 29.72% | 1.04 | 0.95 | 58.07% | 65.30% | 1.16 | 0.04 | 179.55 | 7.20 | 95.84 | 0.67 |
| CHM | CHM | 109 | 1731 | 1.45 | 1.06 | 20.61% | 2.84% | 82.61% | 51.77 | 3.28 | 19.89% | 20.95% | 48.76% | 0.26 | 0.83 | 54.55% | 37.86% | 5.55% | 0.03 | 0.08 | 43.19% | 32.21% | 1.30 | 0.06 | 190.34 | 6.14 | 104.36 | 0.69 |
| CLCC1 | RP | 1 | 12 | 2.37 | 1.00 | 22.89% | 0.00% | 25.00% | 0.01 | 0.33 | 12.78% | 0.00% | 0.00% | 0.00 | 0.00 | | | 33.33% | 0.54 | 0.33 | 54.51% | 100.00% | 0.79 | 0.00 | 137.72 | 2.37 | 1.88 | 0.29 |
| CLN3 | RP | 10 | 147 | 2.23 | 1.03 | 16.06% | 8.51% | 34.01% | 1.75 | 1.17 | 13.96% | 37.43% | 2.72% | 0.00 | 0.06 | 57.99% | 25.00% | 47.62% | 0.52 | 1.97 | 49.10% | 92.66% | 1.29 | 0.06 | 217.27 | 7.86 | 143.39 | 0.73 |
| CLRN1 | RP | 10 | 80 | 1.40 | 1.04 | 19.90% | 4.06% | 60.00% | 9.38 | 1.71 | 15.71% | 23.13% | 23.75% | 0.06 | 0.41 | 53.97% | 63.16% | 51.25% | 0.97 | 1.44 | 52.49% | 94.12% | 1.02 | 0.01 | 143.88 | 15.66 | 221.72 | 0.67 |
| CNGA1 | RP | 8 | 54 | 2.39 | 1.00 | 18.34% | 2.16% | 16.67% | 2.91 | 0.20 | 20.70% | 75.96% | 3.70% | 0.22 | 0.15 | 59.32% | 21.66% | 22.22% | 1.32 | 0.89 | 60.53% | 65.29% | 1.30 | 0.07 | 206.51 | 7.38 | 89.46 | 0.70 |
| CNGA3 | ACHM | 36 | 289 | 1.74 | 1.01 | 13.81% | 14.49% | 31.14% | 1.48 | 0.96 | 7.06% | 56.25% | 7.96% | 0.05 | 0.17 | 53.96% | 31.76% | 35.64% | 0.32 | 0.75 | 50.03% | 74.89% | 1.24 | 0.05 | 209.19 | 5.17 | 70.94 | 0.70 |
| CNGB1 | RP | 28 | 198 | 1.59 | 1.03 | 13.07% | 1.74% | 79.80% | 19.98 | 2.03 | 10.08% | 25.60% | 46.46% | 0.57 | 0.95 | 54.04% | 50.81% | 70.71% | 3.63 | 2.64 | 54.52% | 64.45% | 1.17 | 0.03 | 160.01 | 7.17 | 90.08 | 0.68 |
| CNGB3 | ACHM | 39 | 288 | 1.91 | 0.99 | 14.86% | 12.72% | 12.50% | 0.16 | 0.38 | 6.73% | 73.57% | 10.42% | 0.01 | 0.12 | 52.72% | 63.89% | 32.64% | 0.20 | 0.63 | 54.64% | 92.23% | 1.24 | 0.06 | 205.53 | 6.42 | 67.09 | 0.70 |
| COL11A1 | | 1 | 8 | 2.64 | 1.00 | 6.77% | 2.55% | 100.00% | 0.73 | 2.75 | 6.21% | 61.71% | 37.50% | 0.01 | 0.38 | 34.48% | 33.33% | 12.50% | 0.04 | 0.38 | 40.40% | 100.00% | 1.13 | 0.04 | 178.64 | 3.60 | 29.13 | 0.58 |
| COL18A1 | | 2 | 2 | 0.26 | 1.00 | 13.17% | 0.00% | 50.00% | 34.50 | 3.00 | 19.81% | 14.65% | 50.00% | 0.25 | 0.50 | 55.09% | 1.23% | 0.00% | 0.00 | 0.00 | | | 1.01 | 0.02 | 205.69 | 2.51 | 5.27 | 0.86 |
| COL2A1 | | 1 | 8 | 1.71 | 1.38 | 19.62% | 13.38% | 100.00% | 27.44 | 2.63 | 8.53% | 6.64% | 75.00% | 0.56 | 0.88 | 63.15% | 0.00% | 25.00% | 0.07 | 0.25 | 46.61% | 27.85% | 1.15 | 0.03 | 188.28 | 3.09 | 21.79 | 0.69 |
| COL4A1 | | 1 | 7 | 1.93 | 1.00 | 16.31% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.50 | 0.14 | 188.66 | 3.98 | 37.88 | 0.70 |
| COL4A5 | | 1 | 10 | 1.61 | 1.00 | 12.84% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 100.00% | 11.30 | 4.10 | 57.72% | 80.63% | 1.20 | 0.03 | 194.98 | 8.70 | 85.90 | 0.81 |
| CRB1 | LCA | 47 | 455 | 1.97 | 1.02 | 14.70% | 3.63% | 55.16% | 8.30 | 1.22 | 15.60% | 40.44% | 43.96% | 0.41 | 0.89 | 46.39% | 54.00% | 43.74% | 1.73 | 1.35 | 48.91% | 59.21% | 1.11 | 0.04 | 178.82 | 7.20 | 83.21 | 0.69 |
| CRX | CR | 26 | 236 | 2.11 | 1.00 | 15.62% | 5.73% | 70.34% | 5.51 | 1.39 | 15.62% | 62.69% | 16.95% | 0.05 | 0.26 | 50.74% | 29.92% | 59.32% | 2.23 | 4.22 | 52.94% | 65.95% | 1.33 | 0.07 | 192.40 | 9.58 | 119.49 | 0.72 |
| CTNNA1 | MD | 4 | 10 | 1.51 | 1.30 | 18.54% | 0.00% | 40.00% | 1.50 | 2.20 | 1.60% | 13.10% | 60.00% | 0.23 | 1.20 | 56.33% | 99.44% | 50.00% | 0.04 | 0.80 | 56.60% | 80.51% | 1.42 | 0.09 | 192.93 | 4.01 | 26.94 | 0.71 |
| CWC27 | RP | 1 | 1 | 0.30 | 1.00 | 21.28% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.56 | 0.00 | 80.80 | 3.13 | 1.54 | 0.41 |
| CYP4V2 | RP | 17 | 106 | 1.18 | 1.06 | 22.53% | 3.07% | 86.79% | 35.05 | 3.20 | 16.02% | 33.68% | 15.09% | 0.02 | 0.20 | 49.14% | 61.88% | 3.77% | 0.01 | 0.04 | 32.83% | 50.00% | 1.00 | 0.02 | 144.85 | 4.90 | 28.37 | 0.63 |
| DRAM2 | CR | 8 | 70 | 2.46 | 1.00 | 14.67% | 9.78% | 90.00% | 5.97 | 1.50 | 17.68% | 89.28% | 2.86% | 0.00 | 0.03 | 29.53% | 100.00% | 34.29% | 0.29 | 0.96 | 59.39% | 73.82% | 1.37 | 0.08 | 190.91 | 5.03 | 65.16 | 0.73 |
| DYNC2H1 | RP | 1 | 3 | 3.05 | 1.00 | 33.60% | 0.00% | 33.33% | 0.30 | 0.33 | 35.71% | 100.00% | 0.00% | 0.00 | 0.00 | | | 66.67% | 0.76 | 1.67 | 61.57% | 100.00% | 1.07 | 0.02 | 155.01 | 7.69 | 157.23 | 0.49 |
| EFEMP1 | Drusen | 30 | 249 | 1.77 | 1.00 | 15.28% | 5.98% | 78.71% | 5.15 | 1.84 | 14.24% | 82.36% | 77.91% | 0.24 | 1.55 | 61.84% | 79.37% | 24.10% | 0.18 | 0.66 | 60.03% | 82.55% | 1.43 | 0.10 | 208.55 | 4.31 | 39.45 | 0.72 |
| EYS | RP | 70 | 628 | 2.36 | 1.02 | 15.16% | 2.88% | 65.92% | 9.55 | 1.64 | 13.27% | 27.28% | 23.41% | 0.23 | 0.40 | 57.64% | 42.90% | 72.45% | 2.08 | 2.76 | 52.59% | 76.78% | 1.16 | 0.03 | 172.31 | 7.39 | 108.29 | 0.69 |
| FAM161A | RP | 8 | 62 | 2.12 | 1.05 | 14.58% | 14.56% | 66.13% | 11.60 | 2.02 | 13.90% | 40.33% | 19.35% | 0.27 | 0.35 | 46.78% | 58.46% | 83.87% | 1.83 | 2.77 | 51.04% | 90.53% | 1.10 | 0.02 | 168.97 | 5.66 | 45.07 | 0.65 |
| FLVCR1 | RP | 4 | 27 | 1.01 | 0.93 | 16.45% | 3.53% | 48.15% | 2.58 | 1.85 | 5.93% | 41.36% | 18.52% | 0.15 | 0.37 | 75.14% | 20.00% | 74.07% | 3.76 | 1.78 | 49.80% | 78.55% | 1.06 | 0.02 | 176.65 | 9.58 | 88.25 | 0.70 |
| FZD4 | FEVR | 2 | 9 | 2.78 | 1.11 | 9.17% | 16.13% | 66.67% | 2.59 | 1.11 | 9.48% | 58.83% | 44.44% | 0.12 | 0.56 | 78.35% | 0.00% | 33.33% | 0.02 | 0.56 | 71.29% | 0.00% | 1.40 | 0.10 | 211.97 | 4.37 | 35.44 | 0.66 |
| GNAT2 | ACHM | 2 | 31 | 2.03 | 1.00 | 15.64% | 0.00% | 0.00% | 0.00 | 0.00 | | | 9.68% | 0.01 | 0.10 | 52.77% | 0.00% | 0.00% | 0.00 | 0.00 | | | 1.35 | 0.08 | 230.33 | 4.50 | 55.07 | 0.73 |
| GPR143 | ALB | 6 | 28 | 2.31 | 1.00 | 13.46% | 0.74% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.43 | 0.11 | 209.76 | 5.46 | 61.22 | 0.71 |
| GPR179 | CSNB | 2 | 12 | 2.71 | 1.00 | 13.40% | 3.57% | 50.00% | 0.95 | 0.67 | 21.58% | 100.00% | 0.00% | 0.00 | 0.00 | | | 50.00% | 1.97 | 1.33 | 51.76% | 100.00% | 1.30 | 0.06 | 221.14 | 9.26 | 157.48 | 0.75 |
| GRK1 | CSNB | 1 | 4 | 3.41 | 1.00 | 22.44% | 0.00% | 100.00% | 2.02 | 1.00 | 31.29% | 97.92% | 0.00% | 0.00 | 0.00 | | | 100.00% | 1.88 | 2.25 | 54.96% | 100.00% | 1.28 | 0.04 | 185.11 | 8.14 | 150.90 | 0.76 |
| GRM6 | CSNB | 5 | 17 | 1.69 | 1.12 | 14.61% | 0.00% | 41.18% | 0.42 | 0.82 | 8.63% | 9.56% | 23.53% | 0.04 | 0.24 | 60.87% | 0.00% | 11.76% | 0.02 | 0.18 | 73.19% | 0.00% | 1.19 | 0.06 | 162.84 | 3.47 | 23.22 | 0.66 |
| GUCA1A | CD | 11 | 79 | 2.25 | 1.01 | 16.55% | 9.69% | 41.77% | 2.57 | 0.80 | 17.77% | 58.47% | 25.32% | 0.02 | 0.24 | 57.05% | 65.00% | 69.62% | 1.14 | 1.89 | 60.80% | 93.77% | 1.21 | 0.07 | 175.35 | 4.35 | 34.07 | 0.61 |
| GUCY2D | LCA | 28 | 256 | 2.00 | 1.00 | 14.65% | 6.51% | 48.05% | 5.25 | 0.86 | 17.50% | 71.23% | 17.58% | 0.22 | 0.30 | 61.24% | 35.99% | 60.94% | 1.51 | 2.94 | 53.11% | 74.98% | 1.29 | 0.07 | 197.87 | 5.41 | 64.41 | 0.72 |
| HGSNAT | RP | 11 | 150 | 2.04 | 1.01 | 19.73% | 7.15% | 87.33% | 25.58 | 2.53 | 19.35% | 23.44% | 47.33% | 0.61 | 0.89 | 59.42% | 60.81% | 76.00% | 3.46 | 2.91 | 50.43% | 84.38% | 1.16 | 0.04 | 173.35 | 6.01 | 52.57 | 0.68 |
| HPS6 | ALB | 1 | 2 | 1.98 | 1.00 | 10.33% | 0.00% | 0.00% | 0.00 | 0.00 | | | 50.00% | 0.01 | 0.50 | 60.38% | 0.00% | 100.00% | 0.66 | 1.50 | 67.26% | 91.78% | 1.43 | 0.12 | 224.18 | 5.33 | 53.82 | 0.70 |
| IFT140 | | 8 | 74 | 2.45 | 1.01 | 13.92% | 2.45% | 72.97% | 26.72 | 1.93 | 14.83% | 41.25% | 28.38% | 0.04 | 0.34 | 51.37% | 54.63% | 27.03% | 0.57 | 0.77 | 47.30% | 63.40% | 1.05 | 0.03 | 178.13 | 8.60 | 175.65 | 0.64 |
| IMPDH1 | RP | 6 | 102 | 1.03 | 1.15 | 20.24% | 1.41% | 16.67% | 0.74 | 0.49 | 7.60% | 6.21% | 70.59% | 0.69 | 1.00 | 78.22% | 1.37% | 74.51% | 5.84 | 1.47 | 43.96% | 42.58% | 1.10 | 0.03 | 186.45 | 11.70 | 355.53 | 0.72 |
| IMPG1 | RP | 2 | 10 | 2.57 | 1.00 | 13.09% | 10.11% | 70.00% | 0.63 | 0.60 | 10.29% | 100.00% | 30.00% | 0.16 | 0.30 | 62.18% | 66.67% | 70.00% | 0.25 | 1.60 | 61.95% | 53.47% | 1.41 | 0.10 | 206.75 | 9.02 | 147.19 | 0.72 |
| IMPG2 | RP | 12 | 101 | 2.61 | 1.02 | 14.77% | 3.69% | 58.42% | 4.78 | 1.06 | 13.69% | 30.79% | 9.90% | 0.05 | 0.21 | 57.06% | 57.45% | 27.72% | 0.26 | 0.71 | 44.02% | 68.09% | 1.13 | 0.03 | 197.91 | 7.92 | 135.19 | 0.68 |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------|---------|----|-----|------|------|--------|--------|---------|-------|------|--------|--------|---------|------|------|--------|---------|---------|------|------|--------|---------|------|------|--------|-------|---------|------|
| INPP5E | | 4 | 27 | 1.88 | 1.04 | 9.15% | 3.72% | 37.04% | 0.95 | 1.85 | 1.51% | 35.60% | 7.41% | 0.00 | 0.07 | 42.62% | 100.00% | 92.59% | 3.00 | 4.00 | 58.85% | 80.90% | 1.38 | 0.07 | 197.45 | 4.24 | 56.23 | 0.68 |
| IQCB1 | | 8 | 48 | 2.33 | 1.00 | 10.80% | 18.66% | 18.75% | 1.36 | 0.27 | 14.41% | 34.34% | 14.58% | 0.10 | 0.19 | 41.52% | 51.81% | 85.42% | 3.57 | 3.42 | 38.49% | 71.76% | 1.19 | 0.04 | 214.53 | 4.42 | 35.61 | 0.71 |
| JAG1 | ODT | 1 | 10 | 2.85 | 1.00 | 12.21% | 52.78% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.41 | 0.09 | 195.27 | 6.02 | 179.10 | 0.77 |
| KCNJ13 | LCA | 1 | 1 | 0.04 | 1.00 | 6.74% | 0.00% | 100.00% | 24.14 | 1.00 | 7.38% | 51.12% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.78 | 0.00 | 132.76 | 11.98 | 34.13 | 0.51 |
| KCNV2 | CD | 24 | 159 | 2.06 | 1.01 | 12.71% | 5.01% | 35.85% | 1.77 | 0.75 | 13.62% | 84.52% | 9.43% | 0.01 | 0.08 | 53.98% | 67.72% | 52.20% | 0.92 | 2.87 | 51.85% | 82.53% | 1.27 | 0.07 | 199.15 | 6.01 | 79.68 | 0.73 |
| KIF11 | | 1 | 1 | 1.55 | 1.00 | 16.73% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.83 | 0.00 | 158.06 | 1.13 | 1.25 | 0.67 |
| KIZ | RP | 1 | 2 | 2.77 | 1.00 | 8.86% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 100.00% | 2.97 | 9.50 | 46.16% | 100.00% | 1.41 | 0.10 | 108.94 | 8.33 | 73.84 | 0.77 |
| KLHL7 | RP | 8 | 75 | 2.40 | 0.99 | 9.63% | 0.22% | 70.67% | 13.00 | 1.92 | 13.58% | 30.31% | 24.00% | 0.29 | 0.32 | 55.77% | 93.11% | 84.00% | 3.32 | 5.05 | 49.44% | 89.12% | 1.08 | 0.02 | 155.27 | 4.88 | 46.52 | 0.68 |
| LAMA1 | | 3 | 64 | 1.82 | 1.03 | 15.16% | 11.46% | 73.44% | 14.25 | 1.59 | 11.84% | 3.88% | 62.50% | 0.68 | 1.02 | 51.90% | 29.27% | 68.75% | 1.70 | 3.20 | 49.59% | 34.35% | 1.28 | 0.05 | 230.37 | 2.95 | 26.37 | 0.79 |
| LCA3 | LCA | 1 | 2 | 0.21 | 1.00 | 8.14% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 100.00% | 1.05 | 4.00 | 23.52% | 90.24% | 0.89 | 0.00 | 173.64 | 2.87 | 41.26 | 0.69 |
| LCA5 | LCA | 3 | 22 | 1.68 | 0.95 | 12.37% | 1.64% | 77.27% | 21.91 | 0.95 | 12.25% | 36.27% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.91 | 0.01 | 163.08 | 2.27 | 11.30 | 0.61 |
| LHON | OA | 3 | 9 | 1.93 | 1.00 | 16.85% | 11.09% | 22.22% | 0.26 | 0.44 | 13.18% | 0.00% | 22.22% | 0.01 | 0.22 | 30.78% | 0.00% | 22.22% | 0.05 | 0.44 | 30.19% | 0.00% | 1.29 | 0.07 | 200.32 | 11.21 | 156.87 | 0.75 |
| LRAT | | 1 | 6 | 1.27 | 1.00 | 47.65% | 0.00% | 0.00% | 0.00 | 0.00 | | | 83.33% | 0.18 | 1.00 | 65.92% | 38.33% | 50.00% | 0.10 | 0.50 | 67.11% | 67.84% | 0.93 | 0.01 | 198.61 | 64.14 | 3810.75 | 0.84 |
| MAK | RP | 1 | 6 | 1.97 | 1.00 | 22.73% | 0.00% | 100.00% | 2.96 | 3.17 | 15.83% | 19.65% | 0.00% | 0.00 | 0.00 | | | 50.00% | 0.48 | 2.17 | 47.06% | 97.53% | 1.12 | 0.01 | 163.64 | 8.17 | 284.51 | 0.70 |
| MERTK | | 16 | 199 | 2.32 | 1.01 | 16.10% | 2.09% | 50.25% | 4.65 | 0.78 | 13.72% | 67.63% | 40.70% | 0.09 | 0.58 | 50.57% | 74.20% | 49.25% | 0.26 | 1.11 | 52.78% | 86.12% | 1.12 | 0.03 | 203.52 | 7.47 | 143.86 | 0.70 |
| MFRP | RP | 5 | 95 | 1.52 | 1.05 | 9.39% | 16.23% | 63.16% | 4.52 | 1.24 | 5.81% | 12.76% | 49.47% | 0.14 | 0.84 | 66.66% | 11.94% | 10.53% | 0.11 | 0.38 | 35.89% | 90.00% | 1.45 | 0.12 | 219.12 | 4.58 | 59.51 | 0.72 |
| MFSD8 | | 12 | 132 | 2.50 | 1.02 | 16.29% | 11.16% | 90.91% | 9.35 | 1.48 | 16.31% | 77.20% | 4.55% | 0.00 | 0.06 | 53.64% | 83.33% | 29.55% | 0.71 | 1.06 | 53.56% | 79.47% | 1.16 | 0.05 | 180.60 | 4.76 | 37.14 | 0.68 |
| MKKS | RP | 2 | 41 | 2.79 | 1.07 | 10.91% | 23.12% | 73.17% | 0.82 | 1.10 | 13.35% | 61.34% | 58.54% | 0.13 | 0.59 | 41.18% | 57.57% | 0.00% | 0.00 | 0.00 | | | 0.99 | 0.01 | 199.05 | 17.37 | 849.58 | 0.71 |
| MT-ATP6 | RP | 2 | 30 | 1.87 | 1.00 | 8.18% | 0.02% | 100.00% | 14.49 | 2.27 | 11.39% | 38.65% | 76.67% | 0.64 | 1.57 | 38.90% | 71.42% | 50.00% | 0.25 | 0.57 | 37.80% | 83.24% | 0.90 | 0.01 | 142.39 | 15.17 | 584.20 | 0.73 |
| MT-ND1 | | 2 | 11 | 1.94 | 1.00 | 22.93% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.40 | 0.10 | 204.03 | 6.87 | 77.56 | 0.74 |
| MT-TL1 | | 18 | 121 | 2.45 | 1.00 | 15.52% | 9.29% | 99.17% | 27.19 | 1.83 | 17.96% | 60.58% | 8.26% | 0.01 | 0.09 | 72.61% | 53.87% | 2.48% | 0.03 | 0.05 | 57.33% | 41.27% | 1.38 | 0.08 | 200.53 | 4.72 | 56.76 | 0.73 |
| MYO7A | RP | 49 | 489 | 2.07 | 0.99 | 15.77% | 2.33% | 42.33% | 2.37 | 0.95 | 18.00% | 32.93% | 28.02% | 0.41 | 0.97 | 53.69% | 21.82% | 73.62% | 3.24 | 3.26 | 47.00% | 57.83% | 1.09 | 0.03 | 182.09 | 11.00 | 296.77 | 0.70 |
| NDP | FEVR | 1 | 4 | 2.60 | 1.00 | 6.09% | 25.00% | 50.00% | 10.17 | 2.50 | 6.10% | 0.00% | 50.00% | 0.05 | 0.50 | 68.53% | 50.00% | 0.00% | 0.00 | 0.00 | | | 1.31 | 0.09 | 193.26 | 4.32 | 60.09 | 0.72 |
| NEK1 | RP | 1 | 2 | 2.26 | 1.00 | 9.98% | 0.00% | 0.00% | 0.00 | 0.00 | | | 50.00% | 0.01 | 0.50 | 50.11% | 0.00% | 0.00% | 0.00 | 0.00 | | | 1.44 | 0.11 | 213.59 | 2.76 | 17.96 | 0.72 |
| NHS | MAC | 1 | 5 | 2.52 | 1.00 | 13.94% | 2.33% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.39 | 0.09 | 214.62 | 5.06 | 34.29 | 0.75 |
| NMNAT1 | LCA | 1 | 6 | 2.15 | 1.00 | 22.95% | 0.00% | 100.00% | 6.93 | 2.33 | 25.50% | 11.76% | 100.00% | 2.91 | 2.67 | 70.54% | 0.00% | 100.00% | 2.20 | 2.67 | 60.04% | 11.90% | 1.16 | 0.04 | 208.21 | 9.04 | 31.13 | 0.83 |
| NPHP4 | | 1 | 9 | 2.20 | 1.00 | 19.19% | 0.00% | 0.00% | 0.00 | 0.00 | | | 55.56% | 0.04 | 0.44 | 64.42% | 0.00% | 100.00% | 6.05 | 1.67 | 57.05% | 60.07% | 1.24 | 0.04 | 225.33 | 7.56 | 204.69 | 0.70 |
| NR2E3 | | 27 | 384 | 1.94 | 1.02 | 10.88% | 7.39% | 31.51% | 1.42 | 0.76 | 10.23% | 12.89% | 21.35% | 0.37 | 0.50 | 56.46% | 17.86% | 39.58% | 1.72 | 1.40 | 52.18% | 24.68% | 1.32 | 0.08 | 202.83 | 5.85 | 77.48 | 0.72 |
| NR2F1 | OA | 1 | 5 | 1.87 | 1.00 | 11.70% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.32 | 0.08 | 209.49 | 15.72 | 110.93 | 0.65 |
| NRL | RP | 6 | 26 | 2.01 | 1.04 | 16.78% | 8.27% | 69.23% | 8.00 | 2.19 | 13.37% | 41.91% | 26.92% | 0.12 | 0.31 | 56.64% | 88.18% | 69.23% | 2.80 | 1.85 | 48.05% | 90.56% | 1.16 | 0.03 | 201.74 | 8.27 | 54.69 | 0.68 |
| NYX | CSNB | 7 | 46 | 2.39 | 1.00 | 13.23% | 1.03% | 4.35% | 0.20 | 0.26 | 2.38% | 57.84% | 4.35% | 0.00 | 0.04 | 65.70% | 0.00% | 13.04% | 0.36 | 0.28 | 59.71% | 40.38% | 1.22 | 0.07 | 202.06 | 5.87 | 44.63 | 0.72 |
| OAT | GA | 8 | 143 | 1.93 | 1.14 | 11.96% | 1.96% | 74.83% | 47.65 | 2.17 | 9.98% | 12.27% | 61.54% | 0.22 | 1.01 | 51.11% | 20.33% | 18.88% | 0.12 | 0.31 | 35.56% | 12.35% | 1.13 | 0.03 | 191.12 | 7.10 | 85.81 | 0.67 |
| OCA1 | ALB | 1 | 1 | 0.97 | 1.00 | 10.58% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.93 | 0.02 | 189.77 | 2.07 | 30.82 | 0.52 |
| OCA2 | ALB | 8 | 79 | 1.64 | 1.01 | 24.24% | 1.33% | 7.59% | 0.99 | 0.16 | 27.76% | 3.03% | 3.80% | 0.00 | 0.04 | 75.84% | 0.00% | 0.00% | 0.00 | 0.00 | | | 1.05 | 0.02 | 202.58 | 6.34 | 42.42 | 0.65 |
| OPA1 | OA | 26 | 127 | 1.89 | 1.00 | 17.48% | 5.24% | 1.57% | 0.01 | 0.02 | 12.34% | 0.00% | 16.54% | 0.01 | 0.30 | 57.81% | 8.61% | 0.79% | 0.00 | 0.01 | 68.94% | 0.00% | 1.40 | 0.10 | 210.36 | 5.59 | 71.17 | 0.73 |
| OPN1LW | | 1 | 2 | 2.17 | 1.00 | 10.64% | 0.00% | 0.00% | 0.00 | 0.00 | | | 50.00% | 0.25 | 1.00 | 55.91% | 0.00% | 0.00% | 0.00 | 0.00 | | | 1.46 | 0.12 | 181.40 | 3.60 | 39.21 | 0.74 |
| PAX2 | | 1 | 10 | 2.06 | 1.00 | 30.18% | 0.00% | 10.00% | 1.97 | 0.10 | 24.27% | 23.62% | 10.00% | 0.01 | 0.10 | 77.32% | 0.00% | 10.00% | 0.00 | 0.10 | 74.14% | 0.00% | 1.12 | 0.03 | 207.97 | 4.36 | 28.24 | 0.53 |
| PAX6 | | 7 | 27 | 1.78 | 1.00 | 15.30% | 0.00% | 0.00% | 0.00 | 0.00 | | | 7.41% | 0.00 | 0.00 | 70.69% | | 0.00% | 0.00 | 0.00 | | | 1.08 | 0.04 | 195.64 | 7.60 | 43.89 | 0.69 |
| PCDH15 | RP | 8 | 103 | 2.17 | 1.04 | 14.76% | 0.00% | 74.76% | 9.68 | 2.16 | 10.91% | 24.24% | 33.01% | 0.15 | 0.47 | 56.83% | 62.04% | 87.38% | 4.50 | 3.33 | 51.23% | 65.06% | 1.12 | 0.02 | 162.39 | 6.92 | 98.70 | 0.67 |
| PDE6A | RP | 13 | 108 | 2.61 | 1.02 | 16.48% | 0.02% | 52.78% | 12.80 | 1.38 | 17.06% | 23.69% | 35.19% | 0.19 | 0.51 | 49.45% | 67.39% | 65.74% | 2.14 | 3.56 | 49.36% | 95.54% | 1.09 | 0.03 | 197.01 | 10.30 | 197.25 | 0.71 |
| PDE6B | RP,CSNB | 24 | 272 | 2.62 | 1.01 | 14.75% | 3.35% | 52.21% | 4.48 | 0.93 | 17.05% | 49.30% | 21.32% | 0.08 | 0.28 | 55.09% | 56.89% | 86.03% | 3.37 | 4.06 | 47.35% | 86.55% | 1.12 | 0.03 | 181.70 | 7.22 | 113.36 | 0.71 |
| PDE6C | | 7 | 66 | 2.17 | 1.00 | 14.32% | 6.53% | 40.91% | 1.21 | 0.52 | 11.44% | 79.35% | 4.55% | 0.00 | 0.03 | 47.63% | 100.00% | 45.45% | 1.25 | 2.65 | 45.12% | 68.89% | 1.14 | 0.03 | 209.81 | 10.06 | 141.35 | 0.66 |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----------|------|-----|------|------|------|--------|--------|---------|--------|------|--------|---------|--------|------|------|--------|---------|---------|------|------|--------|---------|------|------|--------|-------|--------|------|
| PDE6G | RP | 2 | 17 | 1.93 | 1.00 | 14.42% | 0.00% | 94.12% | 24.60 | 2.06 | 8.28% | 2.59% | 5.88% | 0.06 | 0.06 | 42.42% | 100.00% | 58.82% | 0.89 | 0.88 | 52.89% | 100.00% | 0.93 | 0.01 | 146.18 | 8.57 | 97.44 | 0.63 |
| PEX1 | | 1 | 1 | 1.12 | 1.00 | 16.41% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.96 | 0.01 | 169.76 | 5.39 | 20.10 | 0.79 |
| PHYH | RP | 3 | 23 | 1.69 | 1.04 | 16.25% | 7.65% | 73.91% | 15.09 | 2.00 | 16.61% | 49.14% | 17.39% | 0.13 | 0.22 | 48.62% | 70.92% | 56.52% | 2.32 | 1.57 | 52.79% | 55.29% | 1.02 | 0.02 | 211.91 | 19.76 | 587.68 | 0.70 |
| PMM2 | | 1 | 8 | 3.17 | 1.00 | 9.85% | 0.00% | 50.00% | 0.51 | 0.50 | 16.16% | 100.00% | 0.00% | 0.00 | 0.00 | | | 50.00% | 1.49 | 1.50 | 43.02% | 100.00% | 1.32 | 0.07 | 189.42 | 3.90 | 34.53 | 0.72 |
| PNPLA6 | | 4 | 44 | 1.09 | 0.95 | 17.85% | 37.45% | 90.91% | 76.83 | 2.05 | 16.65% | 41.66% | 11.36% | 0.03 | 0.14 | 32.67% | 60.43% | 20.45% | 1.52 | 3.11 | 45.99% | 77.18% | 1.11 | 0.03 | 212.07 | 12.77 | 169.49 | 0.70 |
| POC1B | CR | 4 | 39 | 2.01 | 1.00 | 15.65% | 6.44% | 12.82% | 0.80 | 0.13 | 24.00% | 99.92% | 2.56% | 0.00 | 0.03 | 83.77% | 0.00% | 7.69% | 0.17 | 0.41 | 58.99% | 71.49% | 1.33 | 0.08 | 213.24 | 8.42 | 149.54 | 0.73 |
| PROM1 | CR | 52 | 461 | 2.31 | 1.01 | 12.44% | 6.86% | 80.69% | 12.22 | 1.73 | 12.48% | 72.05% | 20.61% | 0.03 | 0.25 | 52.15% | 72.15% | 34.49% | 0.91 | 2.02 | 53.90% | 82.54% | 1.26 | 0.06 | 180.39 | 6.32 | 113.25 | 0.72 |
| PRPF3 | RP | 6 | 68 | 2.19 | 0.99 | 19.71% | 4.63% | 73.53% | 3.76 | 1.07 | 13.84% | 67.07% | 45.59% | 0.61 | 0.50 | 56.20% | 86.15% | 76.47% | 3.17 | 2.24 | 46.35% | 72.56% | 1.03 | 0.02 | 181.57 | 9.51 | 132.07 | 0.72 |
| PRPF31 | RP | 57 | 592 | 2.20 | 1.03 | 15.53% | 1.24% | 48.14% | 6.78 | 1.56 | 11.97% | 41.34% | 18.75% | 0.12 | 0.34 | 45.89% | 68.33% | 64.02% | 2.17 | 2.85 | 52.53% | 86.92% | 1.21 | 0.04 | 178.26 | 7.11 | 146.19 | 0.70 |
| PRPF6 | RP | 4 | 13 | 2.41 | 1.00 | 21.36% | 13.61% | 76.92% | 7.04 | 1.15 | 19.73% | 16.43% | 30.77% | 0.11 | 0.69 | 46.10% | 81.05% | 53.85% | 4.38 | 0.54 | 44.78% | 40.87% | 1.20 | 0.04 | 189.15 | 6.06 | 67.83 | 0.72 |
| PRPF8 | RP | 18 | 172 | 2.33 | 1.02 | 14.57% | 2.46% | 29.65% | 1.73 | 0.65 | 10.35% | 26.14% | 13.95% | 0.02 | 0.15 | 62.66% | 44.31% | 86.05% | 2.78 | 2.72 | 52.30% | 88.57% | 1.12 | 0.03 | 167.83 | 10.67 | 145.07 | 0.69 |
| PRPH2 | CR | 148 | 1218 | 2.05 | 1.01 | 12.34% | 4.47% | 68.72% | 10.28 | 1.89 | 10.10% | 62.00% | 36.37% | 0.07 | 0.58 | 59.10% | 77.08% | 26.27% | 0.69 | 0.85 | 55.77% | 69.43% | 1.36 | 0.08 | 184.62 | 4.76 | 52.09 | 0.71 |
| PRSS56 | MAC | 1 | 2 | 1.98 | 1.00 | 22.54% | 11.52% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.42 | 0.13 | 262.82 | 2.82 | 18.30 | 0.72 |
| PYGM | PD | 3 | 14 | 2.21 | 1.00 | 17.53% | 0.00% | 21.43% | 3.02 | 0.21 | 10.63% | 82.58% | 71.43% | 0.09 | 1.14 | 62.44% | 81.32% | 0.00% | 0.00 | 0.00 | | | 1.42 | 0.11 | 145.64 | 3.71 | 29.34 | 0.74 |
| RAB28 | CR | 1 | 32 | 2.63 | 1.00 | 11.14% | 0.00% | 0.00% | 0.00 | 0.00 | | | 46.88% | 0.13 | 0.47 | 72.50% | 100.00% | 100.00% | 1.32 | 1.41 | 69.75% | 100.00% | 1.32 | 0.06 | 218.28 | 4.60 | 118.18 | 0.69 |
| RAX2 | | 3 | 40 | 2.58 | 1.00 | 20.76% | 19.89% | 90.00% | 6.76 | 1.05 | 22.01% | 52.94% | 7.50% | 0.02 | 0.10 | 62.30% | 34.82% | 32.50% | 0.07 | 0.63 | 48.86% | 77.67% | 1.26 | 0.05 | 208.85 | 10.22 | 118.59 | 0.70 |
| RBP3 | RP | 2 | 17 | 2.06 | 1.00 | 15.14% | 1.73% | 70.59% | 7.06 | 1.35 | 13.79% | 34.18% | 52.94% | 0.67 | 1.53 | 45.94% | 22.22% | 11.76% | 0.01 | 0.12 | 51.40% | 50.00% | 1.05 | 0.02 | 164.58 | 8.97 | 70.22 | 0.67 |
| RDH12 | LCA | 29 | 279 | 1.92 | 1.01 | 18.02% | 11.77% | 58.06% | 22.35 | 1.10 | 19.00% | 37.32% | 33.69% | 0.37 | 0.52 | 49.05% | 22.06% | 34.05% | 1.51 | 2.52 | 57.88% | 84.76% | 0.99 | 0.03 | 179.48 | 3.48 | 20.59 | 0.72 |
| RDH5 | | 9 | 76 | 1.21 | 1.04 | 27.31% | 0.00% | 22.37% | 2.90 | 0.39 | 16.27% | 17.58% | 23.68% | 0.14 | 0.38 | 44.14% | 8.08% | 19.74% | 0.25 | 0.58 | 41.17% | 40.00% | 1.01 | 0.02 | 193.80 | 5.48 | 69.47 | 0.70 |
| REEP6 | RP | 3 | 43 | 2.45 | 1.02 | 18.13% | 0.00% | 44.19% | 1.78 | 1.02 | 15.53% | 15.83% | 9.30% | 0.01 | 0.12 | 61.28% | 50.00% | 90.70% | 2.38 | 5.53 | 57.55% | 97.92% | 1.18 | 0.02 | 184.26 | 11.54 | 415.76 | 0.75 |
| RGR | RP | 1 | 10 | 1.95 | 1.00 | 31.35% | 0.00% | 100.00% | 111.10 | 3.50 | 33.96% | 17.84% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.14 | 0.02 | 218.95 | 6.17 | 66.37 | 0.73 |
| RHO | RP | 107 | 968 | 2.17 | 1.03 | 15.53% | 1.53% | 61.88% | 9.74 | 1.72 | 13.64% | 34.76% | 18.49% | 0.11 | 0.24 | 52.95% | 55.98% | 70.56% | 2.25 | 2.99 | 53.62% | 82.80% | 1.22 | 0.04 | 175.72 | 6.49 | 86.13 | 0.69 |
| RLBP1 | | 6 | 42 | 1.62 | 1.00 | 19.39% | 0.30% | 69.05% | 7.51 | 1.90 | 16.27% | 27.24% | 33.33% | 0.04 | 0.38 | 45.37% | 63.77% | 9.52% | 0.04 | 0.12 | 40.72% | 100.00% | 1.11 | 0.03 | 209.37 | 19.39 | 327.98 | 0.69 |
| RP1 | RP | 115 | 951 | 2.19 | 1.01 | 13.69% | 5.55% | 62.99% | 9.32 | 1.76 | 13.07% | 40.06% | 19.14% | 0.18 | 0.27 | 55.90% | 66.70% | 64.98% | 2.03 | 2.98 | 54.56% | 74.81% | 1.23 | 0.05 | 174.37 | 6.93 | 139.44 | 0.70 |
| RP1L1 | | 18 | 169 | 1.82 | 1.04 | 16.11% | 7.92% | 48.52% | 3.52 | 1.76 | 4.43% | 29.00% | 8.28% | 0.00 | 0.06 | 56.38% | 44.95% | 30.18% | 0.79 | 1.15 | 54.11% | 79.65% | 1.30 | 0.08 | 200.64 | 4.74 | 46.77 | 0.66 |
| RP2 | RP | 28 | 332 | 2.48 | 1.05 | 9.87% | 13.25% | 47.59% | 3.10 | 1.19 | 10.55% | 48.28% | 6.93% | 0.02 | 0.08 | 54.74% | 84.40% | 12.95% | 0.26 | 0.38 | 58.97% | 67.79% | 1.19 | 0.04 | 181.19 | 6.83 | 109.26 | 0.69 |
| RP9 | RP | 9 | 103 | 2.10 | 1.02 | 15.49% | 1.94% | 40.78% | 3.50 | 1.51 | 11.09% | 13.82% | 7.77% | 0.01 | 0.07 | 48.98% | 50.03% | 67.96% | 3.34 | 1.70 | 54.39% | 71.25% | 1.24 | 0.05 | 171.05 | 6.24 | 121.52 | 0.69 |
| RPE65 | LCA | 18 | 82 | 1.15 | 1.06 | 19.28% | 7.57% | 52.44% | 40.13 | 2.65 | 15.03% | 29.14% | 37.80% | 0.24 | 0.65 | 56.35% | 61.75% | 4.88% | 0.19 | 0.05 | 43.10% | 97.60% | 0.97 | 0.02 | 164.35 | 6.64 | 110.77 | 0.65 |
| RPGR | RP | 161 | 1429 | 2.31 | 1.01 | 13.72% | 3.67% | 54.23% | 7.78 | 1.27 | 14.36% | 36.54% | 22.60% | 0.13 | 0.31 | 54.42% | 58.64% | 61.30% | 2.13 | 2.09 | 55.94% | 81.99% | 1.19 | 0.04 | 182.93 | 8.03 | 126.10 | 0.70 |
| RPGRIPI | | 7 | 93 | 2.73 | 1.00 | 13.28% | 0.00% | 4.30% | 0.00 | 0.04 | 7.57% | 25.00% | 15.05% | 0.02 | 0.15 | 51.47% | 0.00% | 70.97% | 1.08 | 3.42 | 43.87% | 85.01% | 1.16 | 0.03 | 206.41 | 9.28 | 284.07 | 0.71 |
| RS1 | RS | 100 | 1186 | 1.93 | 1.00 | 11.86% | 3.50% | 26.81% | 2.41 | 0.58 | 10.68% | 36.67% | 24.79% | 0.10 | 0.37 | 44.28% | 73.17% | 16.95% | 0.35 | 0.59 | 53.00% | 66.36% | 1.34 | 0.09 | 207.50 | 5.45 | 62.27 | 0.72 |
| SAG | | 4 | 47 | 2.99 | 1.04 | 13.28% | 0.00% | 31.91% | 1.19 | 0.53 | 20.98% | 63.99% | 0.00% | 0.00 | 0.00 | | | 14.89% | 0.42 | 0.47 | 54.36% | 89.84% | 1.20 | 0.04 | 228.97 | 9.02 | 87.09 | 0.69 |
| SDCCAG8 | | 1 | 11 | 3.19 | 1.00 | 9.09% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 100.00% | 1.43 | 3.91 | 51.65% | 100.00% | 1.40 | 0.08 | 182.97 | 7.54 | 83.15 | 0.76 |
| SGSH | RP | 1 | 2 | 3.23 | 1.00 | 6.49% | 0.00% | 100.00% | 2.46 | 2.50 | 6.39% | 0.15% | 0.00% | 0.00 | 0.00 | | | 100.00% | 1.38 | 3.00 | 40.38% | 100.00% | 1.32 | 0.05 | 188.58 | 6.61 | 32.76 | 0.73 |
| SLC24A1 | CSNB | 1 | 4 | 2.67 | 1.00 | 13.92% | 0.00% | 0.00% | 0.00 | 0.00 | | | 75.00% | 0.92 | 3.75 | 67.49% | 0.00% | 75.00% | 1.77 | 1.75 | 50.43% | 0.00% | 1.46 | 0.11 | 179.34 | 4.31 | 51.46 | 0.73 |
| SLC24A5 | ALB | 1 | 5 | 1.75 | 1.00 | 13.56% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.36 | 0.10 | 242.22 | 10.66 | 162.99 | 0.76 |
| SLC25A46 | OA | 1 | 4 | 2.15 | 1.00 | 17.71% | 0.00% | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.44 | 0.11 | 195.15 | 6.97 | 144.31 | 0.71 |
| SNRNP200 | RP | 12 | 122 | 2.26 | 1.00 | 19.33% | 0.20% | 73.77% | 18.05 | 2.05 | 15.78% | 29.08% | 30.33% | 0.21 | 0.52 | 51.82% | 69.42% | 74.59% | 2.13 | 3.57 | 49.38% | 96.55% | 1.13 | 0.03 | 166.44 | 6.64 | 88.10 | 0.69 |
| SPATA7 | | 2 | 20 | 2.54 | 1.15 | 13.78% | 4.94% | 5.00% | 0.13 | 0.10 | 28.36% | 0.00% | 35.00% | 0.05 | 0.35 | 62.23% | 13.51% | 90.00% | 1.83 | 3.60 | 40.23% | 90.97% | 1.14 | 0.03 | 197.80 | 8.37 | 98.86 | 0.70 |
| SSBP1 | OA | 3 | 35 | 1.38 | 1.00 | 16.74% | 18.76% | 77.14% | 0.62 | 2.49 | 8.56% | 49.16% | 20.00% | 0.01 | 0.26 | 76.85% | 0.00% | 40.00% | 1.41 | 1.86 | 54.33% | 69.36% | 1.20 | 0.04 | 165.92 | 5.26 | 92.93 | 0.73 |
| TIMP3 | PD | 36 | 322 | 1.71 | 1.01 | 17.51% | 9.49% | 62.11% | 16.35 | 1.84 | 15.26% | 46.54% | 30.75% | 0.14 | 0.51 | 58.46% | 32.56% | 27.02% | 0.47 | 1.00 | 55.24% | 35.32% | 1.39 | 0.09 | 198.27 | 4.99 | 71.86 | 0.71 |
| TOPORS | RP | 6 | 83 | 2.16 | 0.99 | 13.72% | 0.00% | 75.90% | 2.58 | 1.88 | 17.39% | 80.33% | 4.82% | 0.01 | 0.05 | 70.07% | 25.00% | 93.98% | 3.05 | 4.57 | 56.99% | 81.22% | 1.29 | 0.06 | 187.25 | 6.93 | 80.81 | 0.71 |


| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------|------|-----|------|------|------|--------|--------|--------|-------|------|--------|--------|--------|-------|------|--------|---------|---------|-------|------|--------|--------|------|------|--------|--------|--------|-------|------|
| TRNT1 | RP | 1 | 10 | 2.62 | 1.00 | 15.62% | 0.00% | 10.00% | 0.00 | 0.00 | 13.96% | 0.00% | 0.00% | 0.00 | 0.00 | | | 100.00% | 5.69 | 3.60 | 70.63% | 94.80% | 1.15 | 0.02 | 184.94 | 10.53 | 269.64 | 0.68 | |
| TRPM1 | CSNB | 6 | 27 | 2.65 | 1.00 | 14.22% | 0.67% | 0.00% | 0.00 | 0.00 | | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.24 | 0.06 | 207.28 | 7.28 | 63.60 | 0.66 |
| TSPAN12 | FEVR | 1 | 1 | 2.16 | 1.00 | 9.87% | 0.00% | 0.00% | 0.00 | 0.00 | | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.47 | 0.13 | 205.51 | 4.79 | 64.06 | 0.71 |
| TTLL5 | CD | 8 | 56 | 2.34 | 1.00 | 14.86% | 1.59% | 85.71% | 3.36 | 1.68 | 17.98% | 95.01% | 30.36% | 0.03 | 0.27 | 37.89% | 100.00% | 100.00% | 3.07 | 5.32 | 50.65% | 88.34% | 1.32 | 0.06 | 213.57 | 8.00 | 121.73 | 0.76 | |
| TULP1 | | 16 | 165 | 2.57 | 1.05 | 13.77% | 2.78% | 26.06% | 0.53 | 0.41 | 15.25% | 63.18% | 21.82% | 0.07 | 0.40 | 52.38% | 27.71% | 78.18% | 2.56 | 2.96 | 47.46% | 75.10% | 1.15 | 0.04 | 199.61 | 12.24 | 251.64 | 0.70 | |
| TYR | ALB | 12 | 91 | 1.63 | 1.00 | 12.26% | 12.36% | 3.30% | 0.01 | 0.14 | 17.37% | 16.77% | 9.89% | 0.01 | 0.20 | 63.87% | 26.92% | 0.00% | 0.00 | 0.00 | | | | 1.37 | 0.09 | 217.99 | 5.12 | 69.35 | 0.72 |
| TYRP1 | ALB | 1 | 4 | 1.87 | 1.00 | 12.90% | 0.00% | 0.00% | 0.00 | 0.00 | | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.46 | 0.13 | 208.11 | 3.89 | 32.71 | 0.73 |
| USH1C | RP | 14 | 99 | 2.05 | 1.01 | 19.20% | 2.54% | 66.67% | 7.01 | 1.63 | 11.29% | 34.47% | 29.29% | 0.60 | 0.56 | 52.39% | 41.64% | 46.46% | 1.83 | 1.59 | 46.45% | 62.73% | 1.01 | 0.02 | 167.35 | 14.95 | 516.55 | 0.67 | |
| USH1G | RP | 2 | 12 | 1.89 | 1.00 | 13.40% | 11.93% | 33.33% | 0.20 | 0.42 | 9.90% | 0.00% | 50.00% | 0.33 | 1.08 | 56.63% | 0.00% | 58.33% | 2.89 | 5.00 | 58.58% | 1.79% | 1.23 | 0.04 | 234.70 | 8.28 | 94.58 | 0.73 | |
| USH2A | RP | 306 | 2858 | 2.17 | 1.02 | 15.63% | 2.32% | 61.30% | 8.47 | 1.76 | 12.99% | 36.45% | 19.84% | 0.15 | 0.31 | 53.46% | 66.47% | 72.08% | 1.98 | 3.20 | 53.47% | 87.51% | 1.17 | 0.03 | 170.22 | 7.26 | 101.60 | 0.69 | |
| USH2C | RP | 5 | 59 | 1.69 | 0.98 | 16.12% | 3.42% | 88.14% | 10.99 | 2.12 | 11.67% | 20.83% | 32.20% | 0.24 | 0.47 | 58.05% | 90.79% | 79.66% | 2.09 | 2.98 | 52.11% | 88.24% | 1.07 | 0.02 | 156.45 | 6.12 | 82.23 | 0.70 | |
| VHL | VHL | 1 | 2 | 2.78 | 1.00 | 20.14% | 0.00% | 0.00% | 0.00 | 0.00 | | | | 0.00% | 0.00 | 0.00 | | | 0.00% | 0.00 | 0.00 | | | 1.40 | 0.10 | 223.00 | 6.09 | 43.62 | 0.71 |
| VPS13B | RP | 3 | 37 | 2.10 | 1.00 | 25.51% | 0.00% | 48.65% | 1.62 | 0.57 | 19.57% | 85.24% | 18.92% | 0.04 | 0.22 | 43.57% | 4.28% | 70.27% | 1.74 | 1.30 | 49.23% | 94.07% | 0.85 | 0.01 | 172.54 | 9.77 | 192.76 | 0.76 | |
| WDR19 | RP | 2 | 27 | 2.57 | 1.00 | 12.46% | 0.00% | 22.22% | 2.93 | 0.41 | 14.56% | 92.55% | 11.11% | 0.00 | 0.11 | 30.38% | 92.59% | 96.30% | 1.55 | 2.37 | 57.59% | 20.26% | 1.37 | 0.07 | 162.48 | 3.79 | 22.94 | 0.75 | |
| WFS1 | DR | 4 | 21 | 1.87 | 1.00 | 24.03% | 1.16% | 0.00% | 0.00 | 0.00 | | | 19.05% | 0.01 | 1.10 | 62.50% | 21.98% | 0.00% | 0.00 | 0.00 | | | | 1.40 | 0.10 | 208.53 | 4.40 | 52.44 | 0.74 |

Supplementary Table 5: All vessel metrics across genes. Definitions of metrics are given in **Supplementary Table 5**. The table cells have been shaded with lower values in red, intermediate values in white and larger values in green.


| gene | Fractal Dimension | Vessel Density | Average Width | Distance Tortuosity Mean | Squared Curvature Tortuosity Mean | Tortuosity Density Mean |
|----------------|-------------------|----------------|---------------|--------------------------|-----------------------------------|-------------------------|
| <i>ABCA4</i> | 1.33 | 7.65% | 184.81 | 4.81 | 61.6 | 0.71 |
| <i>ABCC6</i> | 1.37 | 8.07% | 196.68 | 6.17 | 80.7 | 0.73 |
| <i>BBS1</i> | 1.18 | 4.56% | 186.86 | 9.66 | 214.9 | 0.7 |
| <i>BEST1</i> | 1.38 | 9.62% | 203.18 | 4.46 | 49.4 | 0.71 |
| <i>CACNA1F</i> | 1.21 | 5.35% | 218.03 | 9.24 | 83.8 | 0.73 |
| <i>CDH23</i> | 1.05 | 2.46% | 198.91 | 7.97 | 177.8 | 0.68 |
| <i>CERKL</i> | 1.16 | 3.51% | 179.55 | 7.2 | 95.8 | 0.67 |
| <i>CHM</i> | 1.3 | 6.20% | 190.34 | 6.14 | 104.4 | 0.69 |
| <i>CNGA3</i> | 1.24 | 5.36% | 209.19 | 5.17 | 70.9 | 0.7 |
| <i>CNGB3</i> | 1.24 | 5.92% | 205.53 | 6.42 | 67.1 | 0.7 |
| <i>CRB1</i> | 1.11 | 4.27% | 178.82 | 7.2 | 83.2 | 0.69 |
| <i>CRX</i> | 1.33 | 7.30% | 192.4 | 9.58 | 119.5 | 0.72 |
| <i>EFEMP1</i> | 1.43 | 10.06% | 208.55 | 4.31 | 39.4 | 0.72 |
| <i>EYS</i> | 1.16 | 3.07% | 172.31 | 7.39 | 108.3 | 0.69 |
| <i>GUCY2D</i> | 1.29 | 6.91% | 197.87 | 5.41 | 64.4 | 0.72 |
| <i>MYO7A</i> | 1.09 | 2.70% | 182.09 | 11 | 296.8 | 0.7 |
| <i>NR2E3</i> | 1.32 | 8.33% | 202.83 | 5.85 | 77.5 | 0.72 |
| <i>PDE6B</i> | 1.12 | 3.00% | 181.7 | 7.22 | 113.4 | 0.71 |
| <i>PROM1</i> | 1.26 | 6.10% | 179.6 | 6.5 | 116.9 | 0.72 |
| <i>PRPF31</i> | 1.21 | 4.10% | 178.26 | 7.11 | 146.2 | 0.7 |
| <i>PRPH2</i> | 1.36 | 8.00% | 184.62 | 4.76 | 52.1 | 0.71 |
| <i>RDH12</i> | 0.99 | 2.93% | 179.48 | 3.48 | 20.6 | 0.72 |
| <i>RHO</i> | 1.22 | 4.47% | 175.72 | 6.49 | 86.1 | 0.69 |
| <i>RP1</i> | 1.23 | 4.59% | 174.37 | 6.93 | 139.4 | 0.7 |
| <i>RP2</i> | 1.19 | 3.65% | 181.19 | 6.83 | 109.3 | 0.69 |
| <i>RPE65</i> | 0.97 | 2.04% | 164.35 | 6.64 | 110.8 | 0.65 |
| <i>RPGR</i> | 1.19 | 4.06% | 182.93 | 8.03 | 126.1 | 0.7 |
| <i>RS1</i> | 1.34 | 8.69% | 207.5 | 5.45 | 62.3 | 0.72 |
| <i>TIMP3</i> | 1.39 | 9.15% | 198.27 | 4.99 | 71.9 | 0.71 |
| <i>USH2A</i> | 1.17 | 3.42% | 170.22 | 7.26 | 101.6 | 0.69 |
| All | 1.25 | 5.75% | 186.52 | 6.45 | 98 | 0.7 |

Supplementary Table 6: Average increase in hypo-AF area stratified by ABCA4 variant severity. ABCA4 patients are grouped based on the severity of their genetic variants as proposed by Cornelis et al. 2022 into groups A, B and C²⁰.


| ABCA4 severity classification | Number of Patients | Variant combination | Average increase in hypo-AF area per year (mm ²) |
|-------------------------------|--------------------|--|--|
| A | 69 | Severe/Severe | 3.11 |
| B | 75 | Intermediate/Intermediate or Severe/Intermediate | 1.59 |
| C | 184 | Mild/* | 0.87 |



Supplementary Figure 3: Rate of progression of hypo-AF in mm² per year for patients in the three severity classification groups of ABCA4. Note that Group A has a higher mean rate of progression than groups B and C, as it corresponds to the group with the highest severity. Error bars denote standard error.











Supplementary Figure 4: Comparison of the mean per-patient extent of macular ring present for patients with different variants (i.e. patients with at least one copy of the given variant) in *ABCA4*. Axes are truncated to exclude 99th percentile outliers. Most variants of *ABCA4* are not associated with a macular ring of raised AF, apart from p.(Gly1961Glu) which we see reflected in the different distributions of ring area in our data.




Supplementary Figure 5: hypo-AF area within 1.5mm of the fovea compared to LogMAR best corrected visual acuity (BCVA) where higher values corresponds to poorer acuity. Axes rescaled to 90th pct of data for legibility. Each circle represents a single patient with mean value across images. Least-squares regression line in red ($\beta=0.083$, $p<0.001$). Mean values for select genes are indicated by red crosses. Comparing hypo-AF

area within 1.5mm of the fovea and LogMAR best corrected visual acuity (BCVA) showed a positive statistical association ($\beta=0.083$, $p<0.001$). However, some genes demonstrated a different relationship from the main trend. For example, in *ABCA4* a worse BCVA was observed than might be expected from hypo-AF coverage, likely because *ABCA4*-associated retinopathy usually initially affects the fovea/central macula. By contrast, *CHM* typically exhibits a spared foveal island despite having significant areas of atrophy, thus accounting for the relatively preserved BCVA.

| | IR Scan and Vessels | Unregistered FAF Scans and Vessels | Overlap of IR and Registered FAF (Scans) | Overlap of IR and Registered FAF (Vessels) |
|---------|--|--|---|--|
| Scans |  |  |  |  |
| Vessels |  |  |  |  |

Supplementary Figure 6: Example showing how vessel tree segmentation improves cross-modality image registration. First row shows the individual and overlaid images, and second rows shows corresponding segmented vessel masks. For the overlaid images, the IR image is rendered in red, while the FAF image is rendered in green, enabling overlap to be assessed by looking at the correspondence between the two-colour channels. Vessel trees were extracted using AIRDetect for both the IR and the FAF image. Results of automatic registration directly on the raw images (scans column) and registration on the vessel trees (vessels column) are shown. In both cases this registration was performed using the SimpleElastix package. As shown by the final column, registering using vessel trees results in better overlap than registering using images alone.



Supplementary Figure 7: 55-degree FAF image with 0.5mm, 1.5mm, and 3mm radial distances shown (corresponding to 1mm, 3mm, and 6mm diameter ETDRS regions), and scale bar with 1mm gradations.

References

1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. *BMJ Open* 2014;4:e004015. Available at: <http://bmjopen.bmj.com/content/4/2/e004015> [Accessed December 4, 2017].
2. Pontikos N, Arno G, Jurkute N, et al. Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom. *Ophthalmology* 2020;127:1384–1394. Available at: <http://dx.doi.org/10.1016/j.ophtha.2020.04.008>.
3. Georgiou M, Robson AG, Fujinami K, et al. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. *Prog Retin Eye Res* 2024;100:101244. Available at: <http://dx.doi.org/10.1016/j.preteyeres.2024.101244>.
4. Lee KE, Pulido JS, da Palma MM, et al. A Comprehensive Report of Intrinsically Disordered Regions in Inherited Retinal Diseases. *Genes* 2023;14. Available at: <http://dx.doi.org/10.3390/genes14081601>.
5. Daich Varela M, Esener B, Hashem SA, et al. Structural evaluation in inherited retinal diseases. *Br J Ophthalmol* 2021;105:1623–1631. Available at: <http://dx.doi.org/10.1136/bjophthalmol-2021-319228>.
6. Delori FC, Dorey CK, Staurengi G, et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. *Invest Ophthalmol Vis Sci* 1995;36:718–729. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7890502>.
7. Strauss RW, Kong X, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11. *JAMA Ophthalmol* 2019;137:1134–1145. Available at: <http://dx.doi.org/10.1001/jamaophthalmol.2019.2885>.
8. Daich Varela M, Laich Y, Hashem SA, et al. Prognostication in Stargardt Disease Using Fundus Autofluorescence: Improving Patient Care. *Ophthalmology* 2023;130:1182–1190. Available at: <http://dx.doi.org/10.1016/j.ophtha.2023.06.010>.
9. Wang Y-Z, Juroch K, Chen Y, et al. Deep Learning-Facilitated Study of the Rate of Change in Photoreceptor Outer Segment Metrics in RPGR-Related X-Linked Retinitis Pigmentosa. *Invest Ophthalmol Vis Sci* 2023;64:31. Available at: <http://dx.doi.org/10.1167/iovs.64.14.31>.
10. Charng J, Xiao D, Mehdizadeh M, et al. Deep learning segmentation of hyperautofluorescent fleck lesions in Stargardt disease. *Sci Rep* 2020;10:16491. Available at: <http://dx.doi.org/10.1038/s41598-020-73339-y>.
11. Lin S, Vermeirsch S, Pontikos N, et al. Spectrum of genetic variants in the commonest genes causing inherited retinal disease in a large molecularly characterised UK cohort. *Ophthalmology Retina* 2024. Available at: <https://www.sciencedirect.com/science/article/pii/S2468653024000137>.
12. Nguyen Q, Woof W, Kabiri N, et al. Can artificial intelligence accelerate the diagnosis of inherited retinal diseases? Protocol for a data-only retrospective cohort study (Eye2Gene). *BMJ Open* 2023;13:e071043. Available at: <http://dx.doi.org/10.1136/bmjopen-2022-071043>.
13. Dice LR. Measures of the Amount of Ecologic Association Between Species. *Ecology* 1945;26:297–302. Available at: <http://www.jstor.org/stable/1932409>.
14. Isensee F, Jaeger PF, Kohl SAA, et al. nnU-Net: a self-configuring method for deep learning-based

biomedical image segmentation. *Nat Methods* 2021;18:203–211. Available at: <http://dx.doi.org/10.1038/s41592-020-01008-z>.

15. Valmaggia P, Friedli P, Hörmann B, et al. Feasibility of Automated Segmentation of Pigmented Choroidal Lesions in OCT Data With Deep Learning. *Transl Vis Sci Technol* 2022;11:25. Available at: <http://dx.doi.org/10.1167/tvst.11.9.25>.

16. Zhang Q, Sampani K, Xu M, et al. AOSLO-net: A Deep Learning-Based Method for Automatic Segmentation of Retinal Microaneurysms From Adaptive Optics Scanning Laser Ophthalmoscopy Images. *Transl Vis Sci Technol* 2022;11:7. Available at: <http://dx.doi.org/10.1167/tvst.11.8.7>.

17. Zhang G, Fu DJ, Liefers B, et al. Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study. *Lancet Digit Health* 2021;3:e665–e675. Available at: [http://dx.doi.org/10.1016/S2589-7500\(21\)00134-5](http://dx.doi.org/10.1016/S2589-7500(21)00134-5).

18. Beucher S, Meyer F. The morphological approach to segmentation: The watershed transformation. In: *Mathematical Morphology in Image Processing*. CRC Press; 2018:433–481. Available at: <https://www.taylorfrancis.com/chapters/edit/10.1201/9781482277234-12/morphological-approach-segmentation-watershed-transformation-beucher-meyer>.

19. Zhou Y, Wagner SK, Chia MA, et al. AutoMorph: Automated Retinal Vascular Morphology Quantification Via a Deep Learning Pipeline. *Transl Vis Sci Technol* 2022;11:12. Available at: <http://dx.doi.org/10.1167/tvst.11.7.12>.

20. Cornelis SS, Runhart EH, Bauwens M, et al. Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity. *Am J Hum Genet* 2022;109:498–507. Available at: <http://dx.doi.org/10.1016/j.ajhg.2022.01.008>.

21. Cornelis SS, Bauwens M, Haer-Wigman L, et al. Compendium of clinical variant classification for 2,247 unique ABCA4 variants to improve genetic medicine access for Stargardt Disease. *bioRxiv* 2023. Available at: <https://www.medrxiv.org/content/10.1101/2023.04.24.23288782v1>.

22. Fakin A, Robson AG, Fujinami K, et al. Phenotype and Progression of Retinal Degeneration Associated With Nullizigosity of ABCA4. *Invest Ophthalmol Vis Sci* 2016;57:4668–4678. Available at: <http://dx.doi.org/10.1167/iovs.16-19829>.

23. Georgiou M, Kane T, Tanna P, et al. Prospective Cohort Study of Childhood-Onset Stargardt Disease: Fundus Autofluorescence Imaging, Progression, Comparison with Adult-Onset Disease, and Disease Symmetry. *Am J Ophthalmol* 2020;211:159–175. Available at: <http://dx.doi.org/10.1016/j.ajo.2019.11.008>.

24. Fujinami K, Zernant J, Chana RK, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. *Ophthalmology* 2015;122:326–334. Available at: <http://dx.doi.org/10.1016/j.ophtha.2014.08.012>.

25. Fujinami K, Lois N, Mukherjee R, et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. *Invest Ophthalmol Vis Sci* 2013;54:8181–8190. Available at: <http://dx.doi.org/10.1167/iovs.13-12104>.

26. Khan KN, Kasilian M, Mahroo OAR, et al. Early Patterns of Macular Degeneration in ABCA4-Associated Retinopathy. *Ophthalmology* 2018;125:735–746. Available at: <http://dx.doi.org/10.1016/j.ophtha.2017.11.020>.

27. Zinkernagel MS, MacLaren RE. Recent advances and future prospects in choroideremia. *Clin Ophthalmol* 2015;9:2195–2200. Available at: <http://dx.doi.org/10.2147/OPHTH.S65732>.

28. Syed R, Sundquist SM, Ratnam K, et al. High-resolution images of retinal structure in patients with choroideremia. *Invest Ophthalmol Vis Sci* 2013;54:950–961. Available at: <http://dx.doi.org/10.1167/iovs.12-10707>.

29. Fujinami K, Sergouniotis PI, Davidson AE, et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. *Am J Ophthalmol* 2013;156:487-501.e1. Available at: <http://dx.doi.org/10.1016/j.ajo.2013.05.003>.
30. Shiraki K, Kohno T, Moriwaki M, Yanagihara N. Fundus autofluorescence in patients with pseudoxanthoma elasticum. *Int Ophthalmol* 2001;24:243–248. Available at: <https://pubmed.ncbi.nlm.nih.gov/14531624/> [Accessed March 24, 2024].
31. Sparrow JR, Duncker T, Woods R, Delori FC. Quantitative Fundus Autofluorescence in Best Vitelliform Macular Dystrophy: RPE Lipofuscin is not Increased in Non-Lesion Areas of Retina. In: *Retinal Degenerative Diseases*. Springer International Publishing; 2016:285–290. Available at: http://dx.doi.org/10.1007/978-3-319-17121-0_38.
32. Shah M, Broadgate S, Shanks M, et al. Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations. *JAMA Ophthalmol* 2020. Available at: <http://dx.doi.org/10.1001/jamaophthalmol.2020.0666>.
33. Laich Y, Georgiou M, Fujinami K, et al. Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings. *Ophthalmology* 2024. Available at: <http://dx.doi.org/10.1016/j.ophtha.2024.01.027>.
34. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet* 2006;368:1795–1809. Available at: <https://pubmed.ncbi.nlm.nih.gov/17113430/> [Accessed March 24, 2024].
35. Cideciyan AV, Jacobson SG. Leber congenital amaurosis (LCA): Potential for improvement of vision. *Invest Ophthalmol Vis Sci* 2019;60:1680. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892385/> [Accessed March 24, 2024].
36. Huang D, Heath Jeffery RC, Aung-Htut MT, et al. Stargardt disease and progress in therapeutic strategies. *Ophthalmic Genet* 2022;43:1–26. Available at: <http://dx.doi.org/10.1080/13816810.2021.1966053>.
37. Lee W, Zernant J, Nagasaki T, et al. Cis-acting modifiers in the ABCA4 locus contribute to the penetrance of the major disease-causing variant in Stargardt disease. *Hum Mol Genet* 2021;30:1293–1304. Available at: <http://dx.doi.org/10.1093/hmg/ddab122>.
38. Fujinami K, Sergouniotis PI, Davidson AE, et al. The clinical effect of homozygous ABCA4 alleles in 18 patients. *Ophthalmology* 2013;120:2324–2331. Available at: <http://dx.doi.org/10.1016/j.ophtha.2013.04.016>.
39. Fakin A, Robson AG, Chiang JP-W, et al. The Effect on Retinal Structure and Function of 15 Specific ABCA4 Mutations: A Detailed Examination of 82 Hemizygous Patients. *Invest Ophthalmol Vis Sci* 2016;57:5963–5973. Available at: <http://dx.doi.org/10.1167/iovs.16-20446>.
40. Grob S, Yonekawa Y, Elliott D. Multimodal imaging of adult-onset foveomacular vitelliform dystrophy. *Saudi J Ophthalmol* 2014;28:104–110. Available at: <http://dx.doi.org/10.1016/j.sjopt.2014.02.001>.
41. Strauss RW, Ho A, Jha A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No. 17). *Am J Ophthalmol* 2023;250:157–170. Available at: <http://dx.doi.org/10.1016/j.ajo.2023.02.003>.
42. Antonelli G, Parravano M, Barbano L, et al. Multimodal Study of PRPH2 Gene-Related Retinal Phenotypes. *Diagnostics (Basel)* 2022;12. Available at: <http://dx.doi.org/10.3390/diagnostics12081851>.
43. Daich Varela M, Georgiadis A, Michaelides M. Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes. *Br J Ophthalmol* 2023;107:1223–1230. Available at: <http://dx.doi.org/10.1136/bjo-2022-321903>.
44. Miere A, Le Meur T, Bitton K, et al. Deep Learning-Based Classification of Inherited Retinal Diseases

- Using Fundus Autofluorescence. *J Clin Med Res* 2020;9. Available at: <http://dx.doi.org/10.3390/jcm9103303>.
45. Miere A, Capuano V, Kessler A, et al. Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. *Comput Biol Med* 2021;130:104198. Available at: <http://dx.doi.org/10.1016/j.compbiomed.2020.104198>.
46. Pontikos N, Woof W, Veturi A, et al. Eye2Gene: prediction of causal inherited retinal disease gene from multimodal imaging using deep-learning. *Research Square* 2022. Available at: <https://www.researchsquare.com/article/rs-2110140/latest> [Accessed March 11, 2024].
47. Fujinami-Yokokawa Y, Ninomiya H, Liu X, et al. Prediction of causative genes in inherited retinal disorder from fundus photography and autofluorescence imaging using deep learning techniques. *British Journal of Ophthalmology* 2021;105:1272–1279. Available at: <http://dx.doi.org/10.1136/bjophthalmol-2020-318544>.
48. Lambertus S, Lindner M, Bax NM, et al. Progression of Late-Onset Stargardt Disease. *Invest Ophthalmol Vis Sci* 2016;57:5186–5191. Available at: <http://dx.doi.org/10.1167/iovs.16-19833>.
49. Ervin A-M, Strauss RW, Ahmed MI, et al. A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned. *Transl Vis Sci Technol* 2019;8:16. Available at: <http://dx.doi.org/10.1167/tvst.8.2.16>.
50. Strauss RW, Muñoz B, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9). *JAMA Ophthalmol* 2017;135:1232–1241. Available at: <http://dx.doi.org/10.1001/jamaophthalmol.2017.4152>.
51. Heath Jeffery RC, Thompson JA, Lo J, et al. Atrophy Expansion Rates in Stargardt Disease Using Ultra-Widfield Fundus Autofluorescence. *Ophthalmol Sci* 2021;1:100005. Available at: <http://dx.doi.org/10.1016/j.xops.2021.100005>.
52. Zhao PY, Branham K, Schlegel D, et al. Automated Segmentation of Autofluorescence Lesions in Stargardt Disease. *Ophthalmol Retina* 2022;6:1098–1104. Available at: <http://dx.doi.org/10.1016/j.oret.2022.05.020>.
53. Hull S, Arno G, Plagnol V, et al. The phenotypic variability of retinal dystrophies associated with mutations in CRX, with report of a novel macular dystrophy phenotype. *Invest Ophthalmol Vis Sci* 2014;55:6934–6944. Available at: <http://dx.doi.org/10.1167/iovs.14-14715>.
54. Fujinami-Yokokawa Y, Fujinami K, Kuniyoshi K, et al. Clinical and Genetic Characteristics of 18 Patients from 13 Japanese Families with CRX-associated retinal disorder: Identification of Genotype-phenotype Association. *Sci Rep* 2020;10:9531. Available at: <http://dx.doi.org/10.1038/s41598-020-65737-z>.
55. Fujinami-Yokokawa Y, Yang L, Joo K, et al. Occult Macular Dysfunction Syndrome: Identification of Multiple Pathologies in a Clinical Spectrum of Macular Dysfunction with Normal Fundus in East Asian Patients: EAOMD Report No. 5. *Genes* 2023;14. Available at: <http://dx.doi.org/10.3390/genes14101869>.
56. Awadh Hashem S, Georgiou M, Ali RR, Michaelides M. RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy. *Cold Spring Harb Perspect Med* 2023. Available at: <http://dx.doi.org/10.1101/cshperspect.a041280>.
57. Tee JLL, Kalitzeos A, Webster AR, et al. QUANTITATIVE ANALYSIS OF HYPERAUTOFLUORESCENT RINGS TO CHARACTERIZE THE NATURAL HISTORY AND PROGRESSION IN RPGR-ASSOCIATED RETINOPATHY. *Retina* 2018;38:2401–2414. Available at: <http://dx.doi.org/10.1097/IAE.0000000000001871>.
58. Shi C, Lee J, Wang G, et al. Assessment of image quality on color fundus retinal images using the automatic retinal image analysis. *Sci Rep* 2022;12:10455. Available at: <http://dx.doi.org/10.1038/s41598-022-13919-2>.

59. Hart WE, Goldbaum M, Côté B, et al. Measurement and classification of retinal vascular tortuosity. *Int J Med Inform* 1999;53:239–252. Available at: [http://dx.doi.org/10.1016/s1386-5056\(98\)00163-4](http://dx.doi.org/10.1016/s1386-5056(98)00163-4).

60. Grisan E, Foracchia M, Ruggeri A. A novel method for the automatic grading of retinal vessel tortuosity. *IEEE Trans Med Imaging* 2008;27:310–319. Available at: <http://dx.doi.org/10.1109/TMI.2007.904657>.